{
  "name" : "zero.sci-hub.se_6298_339671ed9b8533c55a59ef8f5a968a75_demelo-diogo2017.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Strategies to Improve Cancer Photothermal Therapy Mediated by Nanomaterials",
    "authors" : [ "Duarte de Melo-Diogo", "Cleide Pais-Silva", "Diana R. Dias", "André F. Moreira", "Ilídio J. Correia" ],
    "emails" : [ "icorreia@ubi.pt" ],
    "sections" : [ {
      "heading" : null,
      "text" : "P R O G R ES S R EP O R T\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim wileyonlinelibrary.com (1 of 20) 1700073\nStrategies to Improve Cancer Photothermal Therapy Mediated by Nanomaterials\nDuarte de Melo-Diogo, Cleide Pais-Silva, Diana R. Dias, André F. Moreira, and Ilídio J. Correia*\nD. de Melo-Diogo, C. Pais-Silva, D. R. Dias, A. F. Moreira, Dr. I. J. Correia CICS-UBI Centro de Investigação em Ciências da Saúde Universidade da Beira Interior 6200-506 Covilhã, Portugal E-mail: icorreia@ubi.pt\nDOI: 10.1002/adhm.201700073\ndepending on the area under treatment, the maximum temperature and the duration used vary.[3] Hyperthermia at midtemperatures (41.8–45 °C) is capable of exerting a therapeutic effect on malignant cells in hypoxic environments, while eliciting a minimum damage on the surrounding healthy tissues (reviewed in detail in[3]). Additionally, it can also be used to improve the therapeutic outcome of radio- and chemotherapy.[3] On the other hand, hyperthermia at hightemperatures (45–90 °C) can affect both cancer and normal cells, inducing cellular changes (e.g. enzymatic and mitochondrial dysfunctions) and ultimately necrosis (reviewed in detail in[3,4]). However, the equipment and techniques currently available to perform such types of hyperthermia-based treatments present some limitations and need further improvements for attaining a higher selectivity, tissue penetration, and effectiveness.[5] To accomplish that, researchers are currently developing new responsive nanomaterials that due to their small size (usually < 200 nm), can accumulate preferably in\ntumor and induce on-demand hyperthermia, after being subjected to an external stimulus (e.g. magnetic field or light), with a high efficacy and safety.[6–10] Among the different nanomaterials explored, until now, to induce hyperthermia, some can mediate this effect by absorbing light, generated by a laser, and releasing its energy as heat (nanomaterials’ mediated photo thermal therapy (PTT)). This feature has been displayed by several types of nanostructures produced with gold, carbon, copper, molybdenum, tungsten, iron, palladium or conjugated polymers.[7,11–18] Moreover, different strategies are currently being explored to further enhance the photothermal potential of these nanostructures. Compared to laser-induced interstitial thermotherapy (a therapeutic modality that only employs laser light to thermally ablate tumors), nanomaterials’ mediated PTT is less invasive, demands radiation with a lower intensity and its therapeutic outcome is less dependent on the characteristics of the irradiated tissue (e.g. water or hemoglobin content).[19] In addition, PTT mediated by nanomaterials can potentially achieve a higher selectivity towards cancer cells through the use of precisely engineered nanostructures that are specifically internalized by diseased cells.[20–22] Still, it should be noted that the clinical translation of these photothermal agents is challenging since only recently the clinical safety profile of\nThe deployment of hyperthermia-based treatments for cancer therapy has captured the attention of different researchers worldwide. In particular, the application of light-responsive nanomaterials to mediate hyperthermia has revealed promising results in several pre-clinical assays. Unlike conventional therapies, these nanostructures can display a preferential tumor accumulation and thus mediate, upon irradiation with near-infrared light, a selective hyperthermic effect with temporal resolution. Different types of nanomaterials such as those based on gold, carbon, copper, molybdenum, tungsten, iron, palladium and conjugated polymers have been used for this photothermal modality. This progress report summarizes the different strategies that have been applied so far for increasing the efficacy of the photothermal therapeutic effect mediated by nanomaterials, namely those that improve the accumulation of nanomaterials in tumors (e.g. by changing the corona composition or through the functionalization with targeting ligands), increase nanomaterials’ intrinsic capacity to generate photoinduced heat (e.g. by synthesizing new nanomaterials or assembling nanostructures) or by optimizing the parameters related to the laser light used in the irradiation process (e.g. by modulating the radiation wavelength). Overall, the development of new strategies or the optimization and combination of the existing ones will surely give a major contribution for the application of nanomaterials in cancer PTT."
    }, {
      "heading" : "1. Introduction",
      "text" : "Cancer is a highly complex disease and it is responsible for an overwhelming number of deaths worldwide.[1] In the clinic, the mainstream therapeutic options for this disease include surgical resection of the tumor, radiotherapy, chemotherapy, or their combined application. However, in many cases, these treatment regimens are not effective and have associated notorious side effects.\nNowadays, different therapeutic modalities are under clinical evaluation to further improve the effectiveness of cancer treatment. In particular, hyperthermia-based treatments that involve a localized or an unrestricted increase of body temperature have captured the attention of clinicians.[2] However,\nwww.advhealthmat.de\nAdv. Healthcare Mater. 2017, 1700073\nwww.advancedsciencenews.com\nP R O\nG R ES\nS R\nEP O\nR T\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimwileyonlinelibrary.com1700073 (2 of 20)\nAuroLase® therapy (PTT using AuroShell® – PEGylated gold nanoshells), whose initial pre-clinical studies started in the 1990’s, was published and the clinical efficacy of this therapy is yet to be disclosed (ClinicalTrials.gov Identifier: NCT02680535, NCT00848042, NCT01679470).[23]\nIn this progress report, the different strategies described in the literature to improve nanomaterials’ mediated cancer PTT are highlighted. In section 2, an overview of the key parameters that dictate the success of PTT is given. In section 3, the approaches used to enhance nanomaterials tumor accumulation are described. The improvement of nanomaterials’ intrinsic capacity to generate photoinduced heat and the optimization of the parameters related to the laser light are other types of procedures assessed in sections 4 and 5, respectively. Finally, an outlook about the state of the art of nanomaterials’ mediated PTT will be presented (section 6). For the sake of simplicity, this progress report will not cover improvements based on the inclusion of other therapeutics in the nanomaterials (e.g. chemotherapeutic drugs), nor on the utilization of hybrid nanostructures to externally promote tumor accumulation (e.g. by applying magnetic fields)."
    }, {
      "heading" : "2. Cancer Photothermal Therapy Mediated by Nanomaterials",
      "text" : "Cancer PTT mediated by nanomaterials involves the application of nano-sized structures and laser light to irradiate the tumor zone (or metastatic sites) for inducing hyperthermia. Generally, this therapeutic approach starts with the intravenous administration of the nanomaterials, which can become accumulated within the tumor through the enhanced permeability and retention (EPR) effect, by taking advantage of the 3D architecture of blood vessels that supply the tumor, which are characterized by having fenestrae of variable sizes (ranging from 200 to 1200 nm; Figure 1).[24] Moreover, the impaired lymphatic drainage prevents nanomaterials removal, leading to their retention within the tumor microenvironment.[25] Simultaneously, the accumulation of nanomaterials in off-target organs or their rapid elimination from the body (e.g. by renal filtration or through the reticuloendothelial system (RES)) must be avoided.\nOnce inside the tumor tissue, nanomaterials must be capable of migrating and also be homogeneously internalized by cancer cells.[26] However, such internalization may be hampered by tumor’s high interstitial fluid pressure that results from a defective lymphatic drainage.[27]\nAfter nanomaterials successful accumulation within tumor tissue, the PTT is performed by irradiating the tumor zone with a laser light (Figure 1). The effectiveness of this therapeutic modality is dependent on the capacity of nanomaterials to absorb radiation emitted by the laser. A significant or negligible interaction may occur between radiation and biological components like proteins, melanin, hemoglobin, collagen and water.[28] All these biological components have a low or residual absorption within the 750–1000 nm wavelength range (near infrared (NIR)).[28] Therefore, the use of NIR light in cancer PTT is crucial since this radiation displays low off-target interactions and high penetration depth (up to 1–2 cm, that is dependent on the type of tissue under irradiation, the wavelength and the power density\nof the laser light used).[29] The knowledge of the laser light properties is fundamental to maximize light-nanomaterials interactions in order to guarantee a selective and effective hyperthermia, that produces irreversible damages on cancer cells leading to their death by necrosis (such effect is usually attained for temperatures above 50 °C).[4] Moreover, the laser beam is directed to the tumor zone, thus preventing any side effects resulting from nanomaterials that were accumulated in off-target organs.[8,30] Exceptionally, nanomaterials accumulated in skin can cause offtarget hyperthermia and, consequently, origin an undesired outcome since this organ is inevitably irradiated during the PTT.[12]\nTo date, different types of nanomaterials (both organic and inorganic) have been studied for cancer PTT. Among the inorganic nanomaterials, gold-based nanostructures like gold nanocages, nanohexapods, nanorods (GNR), nanoshells and nanostars have been deeply investigated for this biomedical application.[31–34] More recently, researchers also began investigating the applicability of gold nanobipyramids for cancer PTT.[35] Furthermore, carbon-based nanostructures such as carbon nanotubes (CNT) and nanographene oxide (nGO) have also been explored as PTT agents.[12,13] Currently, other inorganic nanostructures based on copper (Cu), molybdenum (Mo), tungsten (W), iron (Fe) and palladium (Pd) are being studied for tumor photoablation.[7,14–17] The Cu-based nanostructures include copper sulfides (e.g. Cu2–xS nanodots, Cu7.2S4 nanocrystals or CuS nanoparticles), selenides (e.g. Cu2–xSe nanocrystals) and bismuth sulfides (e.g. Cu3BiS3 hollow nanospheres).[10,36–39] Regarding Mo and W-based nanomaterials, their oxides (e.g. MoO3–x hollow nanospheres, WO3 nanoparticles) and disulfides (MoS2 and WS2 nanosheets) have been the most selected for this particular biomedical application.[9,15,26,40] Fe-based nanomaterials such iron oxides (e.g. Fe3O4 nanoparticles), sulfides (FeS nanoplates), diselenides (FeSe2 nanoparticles) and prussian blue nanostructures (Fe4[Fe(CN)6]3; PB) have also revealed suitable properties to act as PTT agents.[17,41–43] Regarding Pd-based nanomaterials, researchers have been mainly focused on the applicability of Pd nanosheets for PTT.[7,44] On the other hand, the application of organic nanomaterials for cancer PTT is not so developed as for inorganic materials. In literature, polyaniline (PANI), polypyrrole (PPy), poly(3,4-ethylenedioxythiophene)\nIlídio J. Correia is an Associate Professor with habilitation in the department of Health Sciences at Universidade da Beira Interior. He obtained his B.Sc. and Ph.D. degrees in Biochemistry from Universidade Nova de Lisboa in 1998 and 2003, respectively. He is the PI of Biomaterials and Tissue Engineering group that is focused on the\ndevelopment of new drug delivery systems and bone and skin substitutes, as well as 3D cells culture models of solid tumors for drug screening purposes.\nwww.advhealthmat.de\nAdv. Healthcare Mater. 2017, 1700073\nwww.advancedsciencenews.com\nP R O G R ES S R EP O R T\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim wileyonlinelibrary.com (3 of 20) 1700073\n(PEDOT) and other polymeric materials have been used for cancer PTT.[8,18,45–47]\nOverall, several approaches have been followed to further improve the PTT capacity of these nanostructures (both organic and inorganic). Researchers used different strategies to (i) improve nanomaterials accumulation in tumor, (ii) augment nanomaterials’ intrinsic capacity to produce photoinduced heat or (iii) optimize the parameters related to the laser light. A detailed description of the in vivo therapeutic outcome attained so far by adopting such strategies is summarized in Table S1 (supporting information)."
    }, {
      "heading" : "3. Approaches Used to Improve Nanomaterials Accumulation in Tumors",
      "text" : "In order to mediate an effective and selective hyperthermia upon laser irradiation, nanomaterials must be accumulated in the tumor tissue and also be internalized by cancer cells. The fulfillment of these milestones is affected by nanomaterials’ size, shape, surface charge, and corona composition, as well as by the presence of targeting ligands on their surface (Figure 2). Therefore, the modulation of these features is currently being explored to improve nanomaterials’ mediated PTT (summarized in Table 1)."
    }, {
      "heading" : "3.1. Size",
      "text" : "The blood clearance or off-target accumulation in RES organs (liver and spleen) of nanomaterials are size dependent. In\nliterature, it is described that nanostructures with a size bellow 3–5 nm tend to be rapidly cleared through renal filtration, which constitutes a drawback for their accumulation in the tumor tissue.[48] Moreover, nanostructures with a diameter lower than 50 nm tend to be off-target accumulated in the liver, whereas those larger than 200 nm are more likely to become accumulated in spleen and in liver.[25,27,49] By taking such restrictions into account, nanomaterials aimed to be accumulated within the tumor through the EPR effect must have an appropriate size in the range between 100 and 200 nm.[25] Still, these are general considerations and the optimization of nanomaterials’ size must be performed for each type of photothermal agent in order to attain a proper distribution in the body and therapeutic performance. In this context, Tang and co-workers observed that by reducing the Pd-poly(vinylpyrrolidone) (PVP) nanosheets’ size from 41 to 4.4 nm, their liver uptake decreases from ≈ 45 to ≈ 35% of the total injected dose per gram of tissue (ID g−1).[7] In another study, Akhavan and Ghaderi demonstrated that PEGylated graphene oxide (GO) derivatives with a size of ≈ 61 nm were more effective in cancer PTT than their ≈ 2 µm sized equivalents, since the smaller nanomaterials have a higher tumor-homing capacity (≈ 8.9 vs. ≈ 7.3% ID g−1) and their uptake by liver (≈ 17 vs. ≈ 26% ID g−1) and spleen (≈ 12 vs. ≈ 22% ID g−1) is lower.[50]\nIn addition to the influence of nanomaterials’ size in tumor accumulation, this parameter also has a direct impact on nanomaterials tumor penetration and cellular internalization.[51] Once again, the optimization of the size is decisive for improving nanomaterials therapeutic efficacy. In this context, Wang and co-workers substantiated that PEGylated gold-based capsules with a size of 207 × 105 nm can penetrate and achieve\nwww.advhealthmat.de\nAdv. Healthcare Mater. 2017, 1700073\nwww.advancedsciencenews.com\nFigure 1. Representation of the several events that occur during the PTT mediated by nanomaterials. First nanomaterials are administered and can accumulate in the tumor through the so-called EPR effect. Afterward, the tumor zone is irradiated and nanomaterials induce hyperthermia with high spatial-temporal resolution. Finally, the therapeutic effect is monitored and may have as outcome mice’s survival due to tumor elimination.\nP R O\nG R ES\nS R\nEP O\nR T\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimwileyonlinelibrary.com1700073 (4 of 20)\na wide distribution within the tumor mass, while those with a size of 125 × 95 nm are mainly accumulated in the tumor periphery.[52] Due to this fact, the 207 × 105 nm sized nanocapsules were able to mediate a stronger photothermal effect in vivo. In another work, Wang and co-workers observed that 80 and 100 nm sized PEGylated MoS2 nanosheets are better internalized by cancer cells than those with 300 nm, rendering them as the most suitable for being applied in cancer PTT.[15] In a recent study, Zhang et al. adjusted the size of GO to improve its uptake by cancer cells and their results revealed that the smallest nanosheets (< 50 nm) achieve an higher internalization.[53]"
    }, {
      "heading" : "3.2. Shape",
      "text" : "The nanomaterial’s shape is another feature that has a huge impact on its blood circulation time, tumor uptake, and cellular internalization.[54] Although the shape contribution on these bioprocesses tends to be different for each type of nanostructure, the modulation of this property can be explored for improving nanomaterials’ mediated PTT. Tang and co-workers verified that by coating Pd-PVP nanosheets with silica (transition from a 2D material to a nanosphere), their uptake by cancer cells is increased by ≈ 4.7-fold, leading to an enhanced photothermal effect.[55] Moreover, Wang et al. reported that PEGylated gold nanohexapods display a 1.2- and 3.2-fold higher internalization by cancer cells than PEGylated gold nanocages and PEGylated GNR, respectively.[31] In contrast, under in vivo conditions, PEGylated gold nanocages displayed a low blood circulation time and a high liver uptake (≈ 62% ID g−1), which resulted in a low tumor accumulation (≈ 2.6% ID g−1). On the other hand, PEGylated GNR and gold nanohexapods had superior blood circulation times, that led to a greater tumor accumulation (GNR: ≈ 8.4% ID g−1; nanohexapods: ≈ 7.2% ID g−1). Based on these remarks, the application of PEGylated gold nanohexapods in cancer PTT seems to be a promising strategy due to their improved tumor accumulation and cellular uptake.\nwww.advhealthmat.de\nAdv. Healthcare Mater. 2017, 1700073\nwww.advancedsciencenews.com\nFigure 2. Schematic illustration of the parameters of the nanomaterials that influence their blood circulation, accumulation and penetration in the tumor, and internalization by cancer cells. The key mediators of each process are indicated below the respective panels through the use of roundshaped icons.\nP R O G R ES S R EP O R T\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim wileyonlinelibrary.com (5 of 20) 1700073\nwww.advhealthmat.de\nAdv. Healthcare Mater. 2017, 1700073\nwww.advancedsciencenews.com\nTable 1. Strategies used to improve nanomaterials accumulation in the tumor.\nNanomaterial Optimization Result Ref.\nPEGylated rod-like gold nanoshell capsules\nSize PEGylated gold-based capsules with a size of 385 × 155 nm become less accumulated in the tumor zone when compared to their 125 × 95 nm and 207 × 105 nm sized equivalents;\n[52]\nPEGylated gold-based capsules with a size of 207 × 105 nm can penetrate and achieve a wide distribution in the tumor mass, while those with a size of 125 × 95 nm become accumulated mostly in tumor periphery.\nGO Size Small GO sheets (< 50 nm) achieve the highest internalization by cancer cells. [53]\nPEGylated MoS2 nanosheets Size PEGylated MoS2 nanosheets with a size of 80 and 100 nm are better internalized by cancer cells\nthan those with 300 nm.\n[15]\nPd-PVP nanosheets Size Pd-PVP nanosheets with a size of 4.4 nm have a lower uptake by the liver (≈ 35% ID g−1) than their 41 nm sized equivalents (≈ 45% ID g−1).\n[7]\nPEGylated GO Size PEGylated GO derivatives with a size of 27 nm have a lower uptake by the liver (≈ 11% ID g−1) and spleen (≈ 7% ID g−1) than their 65 nm sized equivalents (≈ 25% ID g−1 of liver; ≈ 25% ID g−1 of spleen).\n[63]\nPEGylated GO Size PEGylated GO derivatives with a size of ≈ 61 nm have a higher tumor-homing capacity (≈ 8.9% ID g−1) and lower uptake by the liver (≈ 17% ID g−1) and spleen (≈ 12% ID g−1) than ≈ 2 µm sized PEGylated nanomaterials (≈ 7.3% ID g−1 of tumor; ≈ 26% ID g−1 of liver; ≈ 22% ID g−1 of spleen).\n[50]\nPEGylated gold nanocages, nanohexapods and nanorods\nShape PEGylated gold nanohexapods display 1.2- and 3.2-fold higher internalization by cancer cells than\nPEGylated gold nanocages and nanorods, respectively;\n[31]\nPEGylated GNR (≈ 8.4% ID g−1) and nanohexapods (≈ 7.2% ID g−1) have a higher tumor-homing capacity than nanocages (≈ 2.6% ID g−1).\nSilica coated Pd-PVP nanosheets Shape Coating of Pd-PVP nanosheets with silica results in a ≈ 4.7-fold increase in their uptake by cancer cells. [55]\nPd-PVP nanosheets immobilized in silica nanoparticles\nShape Electrostatic immobilization of Pd-PVP nanosheets in amine-terminated silica nanoparticles improves their cellular uptake by ≈ 11-fold. [123]\nPEI coated Pd-PVP nanosheets Charge Modification of Pd-PVP nanosheets with PEI increases their cellular internalization by ≈ 1.9-fold. [55]\nAmine-terminated silica coated Pd-PVP nanosheets\nCharge Functionalization of silica coated Pd-PVP nanosheets with amine groups improves their cellular uptake\nby 2.75-fold.\n[55]\nAmine/carboxyl-terminated PEGylated gold nanostars\nCharge Amine/carboxyl-terminated nanostars have a low and enhanced internalization by cancer cells at\npH 7.4 and 6.4, respectively;\n[34]\nAmine/carboxyl-terminated nanostars display a higher tumor accumulation (≈ 10% ID g−1) than nanostars terminated with only carboxyl (≈ 4% ID g−1) or amine groups (≈ 2% ID g−1);\nAmine-terminated nanostars have a high liver uptake (> 120% ID g−1).\nChitosan-pluronic F-68 conjugates encapsulating GNR\nCorona Chitosan-pluronic F-68 conjugates encapsulating GNR have a superior tumor accumulation when compared to non-modified GNR (≈ 117 vs. ≈ 12% ID g−1). [11]\nRBC membrane coated PVP-gold nanocages\nCorona Incorporation of PVP-gold nanocages within vesicles derived from RBC membranes improves their\nblood circulation half-life from 1 to 9.5 h;\n[68]\nRBC coating also improves the tumor accumulation of nanomaterials from 4.37 to 8.34% ID g−1.\nMacrophage cell membrane coated gold nanoshells\nCorona Coating of Au nanoshells with macrophage cell membrane extends their blood circulation time and improves their tumor accumulation from ≈ 1.6 to ≈ 7.5% ID g−1; [33]\nThe coating also reduces the liver and spleen accumulations from about 27 and 14 to about 14 and 9% ID g−1, respectively.\nC18-PMH-mPEG and DSPE-mPEG coated CNT\nCorona C18-PMH-mPEG coated CNT have a higher blood circulation time (t1/2 ≈ 30.8 h) and tumor accumulation (≈ 30% ID g−1) than DSPE-mPEG coated CNT (t1/2 ≈ 3.5 h; 4% ID g−1);\n[62]\nC18-PMH-mPEG coated CNT have a lower liver uptake than DSPE-mPEG coated CNT (≈ 28 vs. ≈ 69% ID g−1).\nC18-PMH-mPEG coated CNT Corona Increasing the PEG length and density of C18-PMH-mPEG coated CNT enhances their blood circulation\ntime, augments tumor and skin accumulations, and reduces uptake by RES organs;\n[12]\nCNT coated with C18-PMH-mPEG with a PEG density and molecular weight of 10% and 5 kDa are considered optimal due to their good circulation time (t1/2 = 12.8 h), high tumor accumulation (≈ 15% ID g−1) and low uptake by skin (≈ 3% ID g−1).\nDSPE-PEG coated CNT Corona DSPE-PEG5400 coated CNT have a higher resistance to protein adsorption than those coated with\nDSPE-PEG2000.\n[83]\nPEGylated rGO and reduced nGO Corona The blood circulation time of C18-PMH-mPEG coated rGO (t’1/2a) ≈ 17.5) and C18-PMH-mPEG coated reduced nGO (t’1/2 ≈ 16.7 h) is superior to that of PEGylated (6-arm branched) nGO (t’1/2 ≈ 5.8 h);\n[63]\nP R O\nG R ES\nS R\nEP O\nR T\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimwileyonlinelibrary.com1700073 (6 of 20)\nwww.advhealthmat.de\nAdv. Healthcare Mater. 2017, 1700073\nwww.advancedsciencenews.com\nNanomaterial Optimization Result Ref.\nThe tumor accumulation of C18-PMH-mPEG coated nanomaterials (≈ 5–6% ID g−1) is 7–8 times higher than that of PEGylated nGO.\nDouble PEGylated reduced nGO Corona Conjugation of amine-terminated C18-PMH-PEG5000 coated reduced nGO with a PEG5000 derivative\n(double PEGylation) improves its blood circulation time from t’1/2 = 18.8 h (t1/2 = 0.19 h) to t’1/2 = 27.7 h (t1/2 = 0.35 h);\n[124]\nThe tumor accumulation is also augmented from 8.8 to 15.5% ID g−1.\nCitrate and mPEG coated CuS nanoparticles\nCorona mPEG coated CuS nanoparticles have a higher blood residence and almost 3-fold greater tumor\naccumulation (7.6% ID g−1) than citrate-CuS nanoparticles;\n[37]\nmPEG coated CuS nanoparticles have a lower uptake by the liver (≈ 23% ID g−1) and spleen (≈ 9% ID g−1) than citrate coated nanomaterials (≈ 44% ID g−1 of liver; ≈ 34% ID g−1 of spleen).\nCitrate, mPEG, and PVP coated CuS nanodots\nCorona PVP coated CuS nanodots display the highest resistance to protein adsorption, followed by mPEG\ncoated nanodots and then by citrate coated nanodots.\n[14]\nPEGylated Cu2–xSe nanoparticles Corona PEGylated Cu2–xSe nanoparticles display a blood circulation time of t’1/2 = 8.14 h (t1/2 = 0.73 h) and a tumor accumulation of 4.4% ID g−1;\n[84]\nNanoparticles also have a low uptake by the liver (≈ 9% ID g−1) and spleen (≈ 8% ID g−1).\nPTMP-PMAAb) coated WO3–x nanodots Corona PTMP-PMAA coated WO3–x nanodots have a tumor accumulation of ≈ 5% ID g−1 and low uptake by the liver (≈ 15% ID g−1) and spleen (≈ 13% ID g−1). [98]\nPEGylated WS2 nanosheets Corona PEGylated WS2 nanosheets possess a high tumor-homing capacity (13% ID g−1) that allows tumor\neradication using irradiation at a relatively low power density.\n[26]\nC18-PMH-PEG coated WS2 nanoflakes Corona C18-PMH-PEG coated WS2 nanoflakes possess a high tumor-homing capacity (≈ 10% ID g−1). The liver and spleen accumulations are ≈ 34 and ≈ 19% ID g−1, respectively. [125]\nPEGylated PB hollow nanocubes Corona Coating of hollow PB nanocubes with PEG improves their blood circulation half-life from 5.6 to 8.7 h. [73]\nRBC-derived membrane coated Fe3O4 nanoclusters\nCorona RBC coated Fe3O4 nanoclusters have about 2.3-fold lower uptake by macrophages than their\nnon-coated equivalents;\n[69]\nRBC coated Fe3O4 nanoclusters have a higher blood retention than their non-coated equivalents and achieve a superior tumor accumulation (≈ 4.9 vs. ≈ 1.3% ID g−1) and lower uptake by the liver (≈ 18 vs. ≈ 32% ID g−1).\nGSHc) modified Pd-PVP nanosheets Corona Functionalization of Pd-PVP nanosheets with GSH increases their blood circulation (t1/2 = 1.25 h) and tumor accumulation to ≈ 4.5% ID g−1;\n[7]\nGSH functionalization reduces the uptake of the nanosheets by the liver (from ≈ 35 to ≈ 8% ID g−1) and spleen (from ≈ 12 to ≈ 2% ID g−1).\nPEGylated Pd-PVP nanosheets Corona PEGylated Pd-PVP nanosheets have a high blood circulation time (t1/2 ≈ 30 h), good tumor accumulation (≈ 8% ID g−1) and low accumulation in RES organs (≈ 11% ID g−1 of liver; ≈ 15% ID g−1 of spleen);\n[44]\nPEGylation using a mPEG-SH:Pd-PVP mass ratio of 1:1 is optimal for the nanosheets;\nIncreasing the PEG molecular weight from 5 to 10 kDa improves the tumor accumulation of the nanosheets from ≈ 8 to ≈ 12% ID g−1.\nPVP-PPy based nanoparticles Corona PVP-PPy based nanoparticles have a low blood circulation time (t1/2 ≈ 12 min) and high uptake by the liver (≈ 49% ID g−1) but achieve a tumor accumulation of ≈ 4% ID g−1.\n[45]\nPEGylated PPy-based nanoparticles Corona Nanoparticles prepared with a Py:Py-COOHd) molar feed ratio of 7:3 are considered as optimal since\nthese display a good compromise between NIR absorption and carboxyl groups for PEG conjugation (inclusion of Py-COOH decreases NIR absorption);\n[65]\nPEGylated nanoparticles have a good blood circulation time (t1/2 ≈ 12.5 h), achieve high tumor accumulation (≈ 18% ID g−1) and demonstrate high uptake by the liver (≈ 45% ID g−1) and spleen (≈ 40% ID g−1).\nPEGylated PEDOT:PSSe) nanoparticles Corona PEGylated PEDOT:PSS nanoparticles possess a high tumor-homing capacity (≈ 28% ID g−1). The liver and spleen accumulations are ≈ 32 and ≈ 17% ID g−1, respectively.\n[8]\nPEGylated gold-Pd nanoplates Corona PEGylated gold-Pd nanoplates display a blood circulation time of t1/2 = 8 h and a tumor accumulation of ≈ 79% ID g−1;\n[126]\nNanoplates have a low uptake by the liver (≈ 17% ID g−1) but display a high accumulation in the spleen (≈ 33% ID g−1) and skin (≈ 16% ID g−1).\nA10 and DUP-1 dual-functionalized PEGylated gold nanostars\nTargeting Dual aptamer functionalized PEGylated gold nanostars mediate a photothermal effect selective for\nprostate cancer cells.\n[75]\nCD44 targeted PEGylated gold nanostars\nTargeting Conjugation of anti-CD44 antibodies to PEGylated gold nanostars increases their tumor accumulation\nby more than 2-fold and reduces their uptake by RES organs.\n[72]\nTable 1. Continued.\nP R O G R ES S R EP O R T\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim wileyonlinelibrary.com (7 of 20) 1700073"
    }, {
      "heading" : "3.3. Surface Charge",
      "text" : "The surface charge exhibited by nanomaterials is another parameter that has to be taken into account when an augmented cellular internalization is aimed. In general, positively charged nanostructures tend to be better internalized by normal and cancer cells since these materials are able to interact with the negatively charged components of cells’ membrane.[56] In particular, cancer cells have on their plasma membrane a higher number of negatively charged components (e.g. phosphatidylserine or sialic acid), which further promote the uptake of positively charged nanomaterials.[57] In this context, Tang and co-workers functionalized Pd-PVP nanosheets with poly(ethyleneimine) (PEI; polycation) and confirmed that this modification increases their cellular internalization by ≈ 1.9-fold.[55] Moreover, the functionalization of silica coated Pd-PVP nanosheets with amine groups also revealed an improved uptake (2.75-fold increase), which is crucial for attaining a heightened photothermal effect.[55]\nwww.advhealthmat.de\nAdv. Healthcare Mater. 2017, 1700073\nwww.advancedsciencenews.com\nNanomaterial Optimization Result Ref.\nDSPE-PEG-RGD coated CNT Targeting DSPE-PEG5400-RGD coated CNT have a superior tumor accumulation (≈ 13% ID g−1) and lower liver uptake (≈ 20% ID g−1) than their equivalents coated with DSPE-PEG2000-RGD (≈ 5% ID g−1 of tumor; ≈ 30% ID g−1 of liver);\n[83]\nDSPE-PEG2000-RGD and DSPE-PEG5400 coated CNT have similar tumor accumulations (≈ 5 vs. ≈ 4% ID g−1).\nDSPE-PEG-Annexin V coated CNT Targeting Annexin V functionalization improves the tumor accumulation of CNT by almost 7-fold (≈ 5% ID g−1). [70]\nHA functionalized nGO Targeting HA-nGO mediates a superior PTT when compared to non-functionalized nGO. [127]\nPluronic F-127-folate conjugates coated nGO\nTargeting nGO functionalized with folate densities of 50 and 100% have a similar tumor accumulation; [71]\nnGO with folate densities of 10 and 25% have a tumor accumulation similar to that of non-functionalized nGO.\nPluronic F-127-folate and Pluronic F-127-RGD conjugates coated nGO\nTargeting Dual-targeted nGO has a higher tumor-homing capacity than single-ligand functionalized\n(folate or RGD) nGO.\n[76]\nDSPE-PEG-RGD coated rGONM and rGO\nTargeting rGONM and rGO functionalized with DSPE-PEG-RGD have a better blood circulation profile than their\nequivalents coated with DSPE-PEG;\n[50]\nRGD functionalization improves the tumor accumulation of PEGylated rGO and rGONM from ≈ 7.3 and ≈ 8.9 to ≈ 22.7 and ≈ 31% ID g−1, respectively;\nRGD functionalization also reduces the uptake of these nanomaterials by the liver (values in % ID g−1: ≈ 26 for rGO-PEG; ≈ 7 for rGO-PEG-RGD; ≈ 17 for rGONM-PEG; ≈ 5 for rGONMPEG-RGD) and spleen (values in % ID g−1: ≈ 22 for rGO-PEG; ≈ 6 for rGO-PEG-RGD; ≈ 12 for rGONMPEG; ≈ 3 for rGONM-PEG-RGD).\nAnti-FSHR antibody functionalized PEGylated nGO\nTargeting Functionalization of PEGylated nGO with anti-FSHR antibody improves the accumulation of these\nnanomaterials in breast cancer lung metastasis from about 5 to 19.7% ID g−1.\n[78]\nFolate and PEG coated CuS nanoparticles\nTargeting Folate coated CuS nanoparticles are rapidly cleared from circulation and have high liver uptake (≈ 35% ID g−1); [30]\nFolate coated CuS nanoparticles have a higher tumor-homing capacity than PEGylated CuS nanoparticles (≈ 9.7 vs. ≈ 6.4% ID g−1).\nAnti-HER-2 antibody functionalized poly(acrylic acid)-W18O49 nanoparticles Targeting HER-2 targeted W18O49 nanoparticles accumulate in HER-2 positive lymphatic metastases and mediate their elimination under NIR laser irradiation. [20]\nHA functionalized WO3 nanoparticles Targeting HA functionalization improves the tumor accumulation of the WO3 nanoparticles from ≈ 5% to 34% ID. [9]\nHER-2 affinity protein functionalized DSPE-PEG Fe5C2 nanoparticles\nTargeting HER-2 targeting functionalization improves the tumor accumulation of Fe5C2 nanoparticles, which then\nmediate the elimination of mice’s tumors with only 3 minutes of laser irradiation.\n[128]\nHA-g-PEG coated PB hollow nanocubes\nTargeting HA-g-PEG coated PB nanocubes mediate a higher hyperthermia under NIR laser irradiation than PEGylated nanocubes (53 °C vs. 43 °C) due to their superior tumor accumulation. [73]\nHA-PANI nanoparticles Targeting PTT mediated by the HA-PANI nanoparticles is selective for CD44 overexpressing cells. [21]\nCetuximab functionalized carboxymethylated PVA-PANI nanoparticles\nTargeting Cetuximab conjugation increases the tumor accumulation of PANI-based nanoparticles from ≈ 1.7 to ≈ 7.1% ID g−1.\n[74]\nAnti-CD44 antibody functionalized PPDSf) nanoparticles\nTargeting PPDS nanoparticles electrostatically complexed with anti-CD44 antibodies mediate a photothermal\neffect selective for cancer cells overexpressing CD44 receptors.\n[22]\na)second phase blood circulation half-life (t’1/2); b)pentaerythritol tetrakis (3-mercaptopropionate)-terminated poly(methacrylic acid) (PTMP-PMAA); c)reduced glutathione (GSH); d)pyrrole:pyrrole-1-propanoic acid (Py:Py–COOH); e)PEDOT:poly(styrenesulfonate) (PEDOT:PSS); f)poly(sodium3-((3-methyl-3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepin-3-yl)methoxy)propane-1-sulfonate) (PPDS).\nTable 1. Continued.\nP R O\nG R ES\nS R\nEP O\nR T\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimwileyonlinelibrary.com1700073 (8 of 20)\nNevertheless, the surface charge of nanomaterials must be properly tuned since it also mediates nanodevices interaction with RES, blood components and elements of the extracellular matrix of the tumor. Nanomaterials with a highly charged surface (positively or negatively) have a greater uptake by RES cells and liver, which has a direct impact on their capacity to reach the tumor tissue.[58] Furthermore, serum proteins can also be adsorbed on nanomaterials’ charged surface, which may lead to the opsonization and clearance of these materials.[59] Moreover, nanomaterials’ surface charge can impair their tumor penetration capacity by favoring interactions with the components of the extracellular matrix of the tumor, such as hyaluronic acid (for positively charged nanomaterials) or collagen (for negatively charged nanomaterials).[27] Owing to these facts, the so-called neutral nanomaterials, which have a zeta potential (ζ) between −10 and +10 mV, are considered the most appealing for cancer-related applications.[27]\nAs discussed above, positively charged nanomaterials may display a higher internalization by cancer cells but an excessive surface charge can also impair nanomaterials accumulation in tumors. To circumvent this pitfall, Wang et al. prepared PEGylated gold nanostars whose charge changes according to the pH of the extracellular environment.[34] Such feature was achieved by controlling the content of amine and carboxyl groups on the surface of the nanostars. In their study, the nanostars with a ratio of four amines to one carboxyl group showed a high differential uptake by cancer cells, i.e., these presented a low internalization at pH 7.4 and an enhanced internalization at pH 6.4. These results may be explained by the surface charge of the nanostars since these are slightly negative at physiological pH (ζ ≈ − 14 mV) and become neutral (ζ ≈ − 6 mV) at the pH characteristic of the tumor microenvironment. In vivo, these carboxyl/amine functionalized nanostars demonstrated a high tumor uptake (≈ 10% ID g−1), which was sufficient to allow tumors elimination under NIR laser irradiation. In stark contrast, nanostars functionalized only with carboxyl (ζ ≈ − 27 mV) or amine (ζ ≈ + 13 mV) groups presented a tumor accumulation of ≈ 4 and ≈ 2% ID g−1, respectively. Therefore, the PTT mediated by these nanomaterials only caused a reduction of the tumor growth. In particular, the majority of the amine functionalized nanostars became accumulated in liver (> 120% ID g−1), thus leading to a lower tumor uptake."
    }, {
      "heading" : "3.4. Corona Composition",
      "text" : "Nanomaterials’ corona composition is another important factor that influences their biological fate. The functionalization of nanomaterials’ surface with PEG is known for improving nano devices hydrophilicity and biocompatibility, features that are fundamental for their successful biological application.[60] Moreover, PEG functionalization can increase nanomaterials’ blood circulation time and also reduces their opsonization and recognition by the RES, thus leading to their improved accumulation in the tumors.[12,44,61] Therefore, the appropriate PEGylation of the different types of nanomaterials has been pursued in order to improve their potential for cancer PTT. Zhou et al. verified that PEGylated CuS nanoparticles have a higher blood residence than citrate coated CuS nanoparticles and almost\n3-fold higher tumor accumulation (7.6% ID g−1).[37] Compared to the PEGylated nanoparticles, the citrate coated nanomaterials displayed a higher uptake by the liver (≈ 44 vs. ≈ 23% ID g−1) and spleen (≈ 34 vs. ≈ 9% ID g−1), resulting in a lower tumor uptake (2.6% ID g−1). Choi et al. encapsulated GNR in photocrosslinked chitosan-pluronic F-68 conjugates and verified that this modification increases nanomaterials tumor accumulation from ≈ 12 to ≈ 117% ID g−1.[11] Due to their superior tumorhoming capacity, the PTT mediated by these nanodevices resulted in tumor eradication while when non-coated GNR were used only a slight decrease in the rate of tumor growth was noticed.\nOn the other hand, CNT coated with PEGylated poly(maleic anhydride-alt-1-octadecene) (C18-PMH-mPEG) showed a blood circulation half-life (t1/2) of ≈ 30.8 h and a tumor accumulation of ≈ 30% ID g−1.[62] In contrast, the CNT coated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(methoxy PEG) (DSPE-mPEG) had a lower tumor accumulation (4% ID g−1), resulting from their lower blood circulation time (t1/2 ≈ 3.5 h) and higher liver uptake (≈ 69 vs. ≈ 28% ID g−1).[62] In other studies, C18-PMH-mPEG was also successfully used to coat reduced nGO and Mo oxide nanosheets, conferring these nanomaterials a tumor-homing capacity that granted tumors eradication upon laser irradiation.[63,64] PEGylation of W, Fe, Pd and conjugated polymer-based nanostructures also allowed the production of materials with a high tumor-homing capacity and that were efficiently applied for cancer PTT.[8,17,26,44,65]\nHowever, the PEGylation of nanomaterials to enhance their biologic properties is not always a straightforward process since the molecular weight and the density of the PEG immobilized on the surface of the nanostructures can affect their biodistribution.[12,66] In this regard, Liu et al. thoroughly investigated the coating of CNT with C18-PMH-mPEG with different PEG lengths (2 and 5 kDa) and densities (5 to 100%).[12] The results revealed that by increasing the PEG length and density, the CNT blood circulation time is extended, which in turn boosts their accumulation in the tumor and skin (CNT accumulation in the skin can induce an off-target heating and simultaneously decrease the amount of radiation that reaches the tumor during PTT). Furthermore, an opposite trend was noticed for CNT accumulation in RES organs. Therefore, the CNT coated with C18-PMHmPEG with a PEG density of 10% and a molecular weight of 5 kDa were considered the most appealing for cancer PTT since these displayed a suitable blood circulation time (t1/2 = 12.8 h), high tumor accumulation (≈ 15% ID g−1) and scarce uptake by skin (≈ 3% ID g−1). Shi and co-workers noticed that PEGylated Pd nanosheets prepared using a thiolated mPEG to Pd-PVP nanosheet mass ratio of 1 to 1 are optimal since the incorporation of a higher PEG mass did not significantly improve the blood circulation time of the nanosheets (t1/2 ≈ 30 h).[44] However, the tumor accumulation of these nanosheets was further increased from ≈ 8 to ≈ 12% ID g−1 by increasing the PEG molecular weight from 5 to 10 kDa, thus allowing tumor eradication upon NIR laser irradiation using a low power density.\nTo further improve nanomaterials accumulation in tumors, other coatings are currently being investigated. A variety of hydrophilic polymers such as poly(carboxybetaine), poly(glycerol), poly(2-ethyl-2-oxazoline), PVP and poly(N-(2-hydroxypropyl) methacrylamide) have been used for such purpose.[67] Zhou et al.\nwww.advhealthmat.de\nAdv. Healthcare Mater. 2017, 1700073\nwww.advancedsciencenews.com\nP R O G R ES S R EP O R T\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim wileyonlinelibrary.com (9 of 20) 1700073\nobserved that PVP coated CuS nanodots display a higher resistance to protein adsorption than those prepared with mPEG, which is fundamental for their efficient tumor accumulation (≈ 3.6% ID g−1) and low uptake by RES organs (≈ 4.3% ID g−1 of liver; ≈ 1% ID g−1 of spleen).[14]\nMoreover, coatings produced with red blood cells’ (RBC) and macrophages’ membranes have been added to nanomaterials’ surface as an alternative to polymeric-based coatings since these coatings exhibit long-blood circulation times.[33,68,69] Piao and co-workers reported that the incorporation of PVP coated gold nanocages within vesicles derived from RBC ghosts amplifies their blood circulation half-life from 1 to 9.5 h.[68] Accordingly, the RBC coating was also responsible for enhancing the tumor accumulation of the nanocages from 4.37 to 8.34% ID g−1 and subsequently, an improved PTT was attained. Recently, Xu et al. demonstrated that by coating gold nanoshells with macrophages’ membranes their blood circulation time is extended and tumor accumulation is amended from ≈ 1.6 to ≈ 7.5% ID g−1.[33] Additionally, the modification of the nanoshells’ surface also reduced their accumulation in liver and spleen, from about 27 and 14 to 14 and 9% ID g−1, respectively. In vivo, the PTT mediated by non-coated gold nanoshells only produced a reduction of the tumor growth, while when macrophage-based coated nanomaterials were used a potent tumor regression was obtained."
    }, {
      "heading" : "3.5. Targeting Ligands",
      "text" : "Nanomaterials’ surface can be further tailored with targeting moieties in order to raise their specificity towards cancer cells. As previously substantiated for CNT, nGO, gold, Cu, W, Fe and PANI-based nanomaterials, the outcome of the PTT mediated by these nanostructures can be improved by targeting receptors overexpressed on the surface of cancer cells.[9,30,70–74] Liang et al. verified that by grafting anti-CD44 antibodies on PEGylated gold nanostars, their accumulation in tumor is enhanced by more than 2-fold and, simultaneously, their uptake by RES organs is reduced.[72] Due to these features, the CD44 targeted nanostars produced a greater therapeutic effect upon laser irradiation than their non-targeted equivalents.[72]\nNanomaterials surface can also be simultaneously functionalized with more than one targeting ligand to further increase the therapeutic outcome achieved with the PTT.[75,76] Jang et al. demonstrated that the dual functionalization of nGO with Pluronic F-127-folate and Pluronic F-127-(arginine-glycine-aspartic acid) (RGD) conjugates (25% density for each ligand) heightens the tumor accumulation of this nanomaterial, leading to tumor eradication upon NIR laser irradiation.[76] In contrast, nGO functionalized only with RGD (density of 25%) or folate (density of 25%)-based conjugates promoted a similar reduction of the tumor growth, however this effect was smaller than that reached by the dual-functionalized nGO.\nThe targeting of the endothelial cells present in tumor vasculature has also been explored for ameliorating the accumulation of nanomaterials in the tumor zone.[77] Neves et al. functionalized CNT with DSPE-PEG-Annexin V to target the phosphatidylserine residues available on the membranes of tumor cells and endothelial cells found in the tumor vasculature.[70] Such\napproach allowed CNT to be almost 7-times more accumulated in tumor (≈ 5% ID g−1).[70] Additionally, the targeting of angiogenic biomarkers present on tumor vasculature has also been exploited to grant nanomaterials accumulation in metastases. To accomplish that, Yang and co-workers functionalized PEGylated nGO with an anti-follicle stimulating hormone receptor (FSHR) antibody and noticed that this functionalization is able to rise the accumulation of nanomaterials in breast cancer lung metastasis from about 5 to 19.7% ID g−1.[78]\nYet, the functionalization of nanomaterials is still regarded as a complex and a delicate process. In some cases, the complete functionalization of nanomaterials’ surface does not guarantees an improvement of nanomaterials accumulation in tumors.[71,79] In fact, targeted nanomaterials demand an appropriate ligand density for accomplishing such purpose. Lee et al. verified that nGO coated with Pluronic F-127-folate conjugates with folate densities of 50 and 100% display a similar tumorhoming capacity.[71] In contrast, nanomaterials functionalized with lower folate densities (10 and 25%) exhibited a tumor accumulation comparable to that of non-folate functionalized nGO, and, therefore, mediated a weaker photothermal effect. Furthermore, the selectivity of targeted nanostructures can also be hampered by the formation of a protein corona on their surface.[80] To circumvent this possibility some nanomaterials are engineered to only expose their targeting moieties upon reaching the tumor microenvironment.[81] Alternatively, the immobilization of targeting ligands in PEG segments with higher lengths while leaving shorter PEG segments non-functionalized can attenuate the loss of selectivity mediated by the adsorption of serum proteins on the surface of nanomaterials.[82] In addition, the length of the spacer-arm to each the target ligand binds is also a decisive parameter for governing the biodistribution of these nanomaterials. To address this issue, Liu and co-workers coated CNT with DSPE-PEG-RGD conjugates containing different PEG lengths (2000 or 5400 Da). Their results revealed that CNT coated with DSPE-PEG5400-RGD show a superior tumor accumulation (≈ 13% ID g−1) and lower uptake by liver (≈ 20% ID g−1) than the DSPE-PEG2000-RGD coated CNT (≈ 5% ID g−1 of tumor; ≈ 30% ID g−1 of liver).[83] Interestingly, CNT coated with DSPE-PEG2000-RGD had only a slightly higher tumor accumulation than those coated with DSPE-PEG5400 (≈ 4% ID g−1). Such may be attributed to the higher resistance to protein adsorption displayed by the CNT coated with DSPEPEG5400. This fact may also be the reason for the higher blood circulation time (t1/2 ≈ 2 h) and lower liver accumulation displayed by CNT functionalized with DSPE-PEG5400 derivatives, thus emphasizing the importance of the PEG length on the biodistribution of targeted nanomaterials."
    }, {
      "heading" : "4. Strategies Used to Augment Nanomaterials’ Capacity to Produce Photoinduced Heat",
      "text" : "The application of nanomaterials with a high NIR absorption and good photothermal conversion efficiency for cancer PTT is highly desirable since these can produce a larger temperature variation upon NIR irradiation (Figure 3). Therefore, researchers are currently using a variety of strategies to obtain nanomaterials with these desired properties (see Table 2 for further details).\nwww.advhealthmat.de\nAdv. Healthcare Mater. 2017, 1700073\nwww.advancedsciencenews.com\nP R O\nG R ES\nS R\nEP O\nR T\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimwileyonlinelibrary.com1700073 (10 of 20)"
    }, {
      "heading" : "4.1. Production of New Nanomaterials",
      "text" : "Nanomaterials’ capacity to produce heat under NIR laser irradiation has been enhanced through the synthesis of new materials with a higher photothermal conversion efficiency and NIR absorption.[9,40,43,84] Copper sulfide nanostructures have been produced with different Cu to S stoichiometric ratios in order to obtain more efficient photothermal agents. In recent studies, nanocrystals based on Cu9S5 showed a photothermal conversion efficiency of ≈ 26%, while those composed of Cu7.2S4 had a photothermal conversion efficiency ≈ 57% (at 980 nm).[10,85]\nRegarding Pd and gold-based nanostructures, their photothermal capacity is influenced by their shape and this parameter has been optimized during nanostructures synthesis to obtain agents with an improved PTT capacity.[31,86] Xiao et al. prepared porous Pd nanoparticles that have a higher NIR absorption than that displayed by Pd nanocubes, non-porous Pd nanoparticles, and Pd polyhedrons.[86] Such feature makes their application in cancer PTT more advantageous.[86] In addition, the photothermal conversion efficiency of gold nanomatryoshkas, nanocages, bellflowers, nanobipyramids and nanorods can be superior to 60%, which makes them one of the most promising gold-based photothermal agents (Table 2).[87–91]\nMoreover, nanomaterials based on Mo, W, Fe, and conjugated polymers with an upgraded photothermal capacity have also been produced for application in cancer PTT.[42,92–95] Yang et al. prepared PEGylated FeS nanoplates with a ≈ 17 times higher NIR absorption than that displayed by Fe3O4 nanoparticles.[42] Consequently, the FeS nanoplates were able to mediate the production of a photoinduced heat to about 70 °C while, in the same conditions, the Fe3O4 nanoparticles only increased\nthe temperature to ≈ 45 °C. In another work, Kim and co-workers synthesized poly(3,4propylenedioxyselenophene) (PProDOS) nanoparticles that had a slightly superior NIR absorption than PEDOT nanoparticles and, consequently, produced a higher photoinduced heat (ΔT ≈ 10 °C vs. ΔT = 6 °C).[95]\nAnother strategy used to improve nanomaterials’ mediated PTT comprises the synthesis of materials that are responsive to the pH or oxygen gradient of the tumor microenvironment. PANI-based nanoparticles in acidic media (≈ pH 3), in contact with hydroxyl radicals or in the presence of bio-dopants, change from the emeraldine base (EB) to the emeraldine salt (ES) form, that displays an augmented NIR absorption.[18,96] Recently, Ju and co-workers polymerized a PANI shell at the surface of gold nanoparticles, enabling an heightened NIR absorption at the range of pH values found in tumor microenvironment.[97] In particular, PANI-based nanoparticles with a 16 nm gold core displayed the lowest NIR absorption at pH 7.4 while at pH 6.5 these had a high absorption. This difference led to a temperature increase under NIR laser irradiation to ≈ 40 °C and ≈ 53 °C,\nThe production of hybrid nanostructures composed by different types of photothermal agents has also been pursued to obtain materials with an improved photothermal capacity. These structures are usually obtained by combining photothermal agents with gold, PPy or polydopamine due to the ability of the latter be grown or polymerized on the surface of nanomaterials.[99–104] In this regard, Li et al. verified that by coating PEI-gold nanostars with polydopamine, their photothermal conversion efficiency is improved from 36.1 to 49.9% (at 808 nm).[104] In other works, PEGylated gold-silver star- and urchin-shaped hybrid nanostructures demonstrated a photothermal conversion efficiency of 79.01 and 80.4% (at 808 nm), respectively, which are one of the highest efficiencies reported so far (see Table 2 for further details).[99,100]"
    }, {
      "heading" : "4.2. Optimization of Nanomaterials’ Size",
      "text" : "Upon irradiation, nanomaterials can scatter and absorb light, being this latter phenomenon responsible for the heat generation.[105] Smaller nanomaterials scatter less light and can display a faster heat transfer to the surrounding environment due to their large surface area/volume ratio.[106,107] In this way, nanomaterials with an improved photothermal capacity can be obtained by selecting nanostructures based on their size.[7,15,107,108] Wang et al. verified that despite 100 nm sized MoS2 nanosheets exhibiting a higher NIR absorption than their 80 nm equivalents, the latter are capable of producing a greater temperature variation under laser irradiation due\nwww.advhealthmat.de\nAdv. Healthcare Mater. 2017, 1700073\nwww.advancedsciencenews.com\nP R O G R ES S R EP O R T\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim wileyonlinelibrary.com (11 of 20) 1700073\nwww.advhealthmat.de\nAdv. Healthcare Mater. 2017, 1700073\nwww.advancedsciencenews.com\nTable 2. Strategies used to improve nanomaterials’ capacity to produce photoinduced heat.\nNanomaterial Optimization Result Ref.\nUrchinlike gold nanoparticles New material Photothermal conversion efficiency of 11% (at 808 nm). [101]\nGold nanohexapods New material Photothermal conversion efficiency of 29.6% (at 808 nm). [88]\nGold/SiO2 nanoshells New material Photothermal transduction efficiency of ≈ 34% (at 815 nm). [90]\nGold nanoshells New material Photothermal transduction efficiency of 39% (at 810 nm). [87]\nNanoporous gold disks New material Photothermal conversion efficiency of ≈ 56% (at 700–900 nm). [129]\nGold nanomatryoshkas New material Photothermal transduction efficiency of 63% (at 810 nm). [87]\nGold nanocages New material Photothermal conversion efficiency of 63.6% (at 808 nm). [88]\nGold bellflowers New material Photothermal conversion efficiency of 74% (at 808 nm). [89]\nGold nanobipyramids New material Photothermal conversion efficiency depends on the radius of the nanostructures (51–≈ 90%, at 809 nm). [91]\nGold nanorods New material Photothermal conversion efficiency depends on the aspect ratio of the\nnanostructures (22.1–95%).\n[88,90,91,130]\nGold nanocages, nanohexapods, and nanorods New material Gold nanocages generate a photoinduced heat similar to that of GNR and nanohexapods, but at a ≈ 3-fold lower concentration. [31]\nPEGylated Cu nanowires New material Photothermal conversion efficiency of 12.5% (at 808 nm). [131]\nCu2–xSe nanocrystals coated with hydrolyzed poly(isobutylene-alt-maleic anhydride)-oleylamine conjugates\nNew material Photothermal transduction efficiency of 22% (at 800 nm). [38]\nCu9S5 nanocrystals modified with aminocaproic acid New material Photothermal conversion efficiency of 25.7% (at 980 nm). [85]\nPEGylated Cu3BiS3 hollow nanospheres New material Photothermal conversion efficiency of 27.5% (at 980 nm). [39]\nBSA-Gd:CuS nanoparticles New material Photothermal conversion efficiency of 32.3% (at 980 nm). [132]\nFerritin-CuS New material Photothermal conversion efficiency of ≈ 47% (at 808 nm). [133]\nSilica coated Cu1.75S nanoparticles New material Photothermal conversion efficiency of 54.13% (at 808 nm). [134]\nCu7.2S4 nanocrystals coated with a hydrolyzed poly(maleic anhydride)-oleylamine based amphiphile\nNew material Photothermal conversion efficiency of 56.7% (at 980 nm). [10]\nPEGylated Cu2–xSe nanoparticles New material Photothermal conversion efficiency of 64.8% (at 808 nm). [84]\nPEGylated Mo oxide nanospheres and nanoribbons New material Mo oxide nanorods (synthesized in the absence of PEG) have a weak NIR\nabsorption, while Mo oxide nanospheres and nanoribbons (synthesized in the presence of PEG) have high NIR absorption.\n[135]\nPEGylated MoO3–x hollow nanospheres New material MoO3–x hollow nanospheres prepared in the presence of PEG have an\nenhanced NIR absorption and a photothermal conversion efficiency of 22.64% (at 808 nm).\n[40]\nChitosan functionalized MoS2 nanosheets New material Photothermal conversion efficiency of 24.37% (at 808 nm). [136]\nPEGylated MoS2 nanoflakes New material Photothermal conversion efficiency of 27.6% (at 808 nm). [92]\nLayered MoS2 hollow spheres New material Layered MoS2 hollow spheres have a higher NIR absorption than MoS2\nnanosheets and a photothermal conversion efficiency of 34.46% (at 808 nm).\n[137]\nPluronic F-127 coated MoSe2 nanodots New material Photothermal conversion efficiency of 46.5% (at 785 nm). [138]\nRadar-like MoS2 nanoparticles New material Radar-like MoS2 nanoparticles have a higher photothermal conversion\nefficiency (53.3%) than MoS2 nanoflowers (18.2%) and MoS2 microspheres (15.2%, at 808 nm).\n[139]\nPVP coated MoSe2 nanosheets New material Photothermal conversion efficiency of 57.9% (at 808 nm). [140]\nPEGylated Mo oxide nanosheets New material Mo oxide nanosheets display a pH dependent NIR absorption that is governed\nby their degradation. In healthy tissues, the nanosheets have a fast degradation rate. In the tumor microenvironment (slightly acidic) the nanosheets degrade slowly, thereby retaining their NIR absorption.\n[141]\nHA functionalized WO3 nanoparticles New material Photothermal conversion efficiency of 11.78% (at 808 nm). [9]\nPVP coated Rb0.27WO3 nanorods New material Photothermal conversion efficiency of 17.8% (at 808 nm). [120]\n(NH4)xWO3 nanocubes New material Photothermal conversion efficiency of 39.4% (at 1064 nm). [93]\nWO3 nanoparticles New material Photothermal conversion efficiency of 41.96% (at 808 nm). [9]\nPTMP-PMAA coated WO3–x nanodots New material WO3–x nanodots NIR absorption is enhanced in acidic and in hypoxic\nenvironments.\n[98]\nFe3O4 nanoparticles New material Photothermal conversion efficiency of 6.4% (at 808 nm). [103]\nP R O\nG R ES\nS R\nEP O\nR T\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimwileyonlinelibrary.com1700073 (12 of 20)\nwww.advhealthmat.de\nAdv. Healthcare Mater. 2017, 1700073\nwww.advancedsciencenews.com\nNanomaterial Optimization Result Ref.\nFe3O4 nanoparticles New material Fe3O4 nanoparticles functionalized with PEG produce a higher photoinduced\nheat than Fe3O4 nanoparticles stabilized with PVP, PVA, polyglutamic acid, xalic acid, citrate, glutamic acid, and diethylene glycol.\n[109]\nPEGylated FeS nanoplates New material PEGylated FeS nanoplates have ≈ 17 times higher NIR absorption than Fe3O4 nanoparticles, thus producing a superior photoinduced heat\n(≈ 70 °C vs. ≈ 45 °C).\n[42]\nPEGylated FeSe2 New material PEGylated FeSe2 nanoparticles have ≈ 9 times higher NIR absorption than Fe3O4-based nanoparticles, thus generating a superior photoinduced heat\n(≈ 65 °C vs. ≈ 31 °C).\n[43]\nDenatured BSA coated Mn2+ doped iron oxide nanoparticles\nNew material Photothermal conversion efficiency of 26.9% (at 808 nm). [142]\nFe(III)-gallic acid nanoparticles New material Photothermal conversion efficiency of 66.8% (at 808 nm). [143]\nPd nanocubes, nanoparticles, porous nanoparticles, and polyhedrons\nNew material Porous Pd nanoparticles have a higher NIR absorption than Pd nanocubes,\nPd nanoparticles, and Pd polyhedrons.\n[86]\nPEG coated gold-PANI nanoparticles New material PANI-based nanoparticles with a 16 nm gold core display the lowest NIR\nabsorption at physiological pH (7.4) and high NIR absorption at acidic pH (6.5). Thereby, at pH 7.4 these generate a photoinduced heat to ≈ 40 °C while at pH 6.5 the temperature reaches ≈ 53 °C.\n[97]\nPVP coated PPy nanoparticles New material Photothermal conversion efficiency of 44.7% (at 808 nm). [45]\nTosylate doped poly(2TMOI-OEGMA)a)-PPy nanoparticles\nNew material Photothermal transduction efficiency of 46.9% (at 808 nm). [94]\nPEDOT nanotubes and PEDOT:PSS nanoparticles New material PEDOT nanotubes have almost a 2-fold higher NIR absorption than\nPEDOT:PSS nanoparticles and thus generate a superior photoinduced heat (ΔT ≈ 16 °C vs. ΔT ≈ 8 °C).\n[144]\nPProDOS nanoparticles New material PProDOS nanoparticles have a slightly superior NIR absorption than\nPEDOT nanoparticles, thus producing a higher photoinduced heat (ΔT ≈ 10 °C vs. ΔT = 6 °C).\n[95]\nPCPDTBTb) and PCPDTBSec) nanoparticles New material PCPDTBT nanoparticles produce a slightly higher photoinduced heat than\nPCPDTBSe nanoparticles (ΔT ≈ 35 °C vs. ΔT ≈ 30 °C). [145]\nPluronic F-127 coated PCPDTBSe nanoparticles New material Pluronic F-127 coated PCPDTBSe nanoparticles mediate a higher photoinduced\nheat (ΔT = 47 °C) than Pluronic F-127 coated PCPDTBSe nanofibers (ΔT ≈ 35 °C) and PCPDTBSe nanoparticles (ΔT ≈ 35 °C).\n[47]\nPPDS nanoparticles New material Photothermal conversion efficiency of 31.4% (at 808 nm). [22]\nGold nanopopcorn conjugated CNT New material The NIR absorption of the hybrid nanostructures is enhanced by increasing\nthe content of gold nanopopcorn immobilized on CNT.\n[146]\nPEG-GO/CuS nanocomposites New material PEG-GO/CuS nanocomposites produce a higher photoinduced heat (ΔT = 24.9 °C) than GO (ΔT = 14 °C) due to their superior NIR absorption. [147]\nPolydopamine coated Fe3O4 nanoparticles New material Increasing the thickness of the polydopamine shell improves the NIR\nabsorption of the hybrid nanostructures.\n[103]\nPhotothermal conversion efficiency of 13.1% (at 808 nm).\nPEGylated Fe-Fe3O4 nanoparticles New material Photothermal conversion efficiency of 20.3% (at 808 nm). [148]\nPPy coated GNR incorporating Fe3O4 nanoparticles New material Photothermal conversion efficiency of 23.9% (at 808 nm). [149]\nPPy coated urchinlike gold nanoparticles New material Increasing the thickness of the PPy shell from 3.5 to 15.3 nm improves the\nphotothermal conversion efficiency of the hybrid nanostructures from 18.6 to 27.5% (at 808 nm).\n[101]\nPEGylated gold-Pd nanoplates New material Photothermal conversion efficiency of 28.6% (at 808 nm). [126]\nFe3O4 coated PPy nanoparticles New material Photothermal conversion efficiency of 39.15% (at 808 nm). [150]\nPPy coated Fe3O4 superstructures New material Increasing the thickness of the PPy shell improves the NIR absorption of the\nhybrid nanostructures;\n[102]\nNanostructures with a 16 nm thick PPy shell display the highest photothermal transduction efficiency (49% at 808 nm).\nPolydopamine coated PEI-gold nanostars New material Polydopamine coating improves the photothermal conversion efficiency of\nthe PEI-gold nanostars from 36.1 to 49.9% (at 808 nm).\n[104]\nTable 2. Continued.\nP R O G R ES S R EP O R T\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim wileyonlinelibrary.com (13 of 20) 1700073\nwww.advhealthmat.de\nAdv. Healthcare Mater. 2017, 1700073\nwww.advancedsciencenews.com\nNanomaterial Optimization Result Ref.\nGold/Au2S nanoshells New material Photothermal transduction efficiency of ≈ 58% (at 815 nm). [90]\nGold nanopopcorn-iron oxide cluster nanoparticles New material Photothermal conversion efficiency of 61% (at 808 nm). [151]\nPEGylated gold-silver nanostars New material Photothermal conversion efficiency of 79.01% (at 808 nm). [99]\nPEGylated hollow gold-silver alloy urchin-shaped nanostructures\nNew material Photothermal conversion efficiency of 80.4% (at 808 nm). [100]\nPVA coated PPy nanoparticles Size 50 nm PVA coated PPy nanoparticles produce a higher photoinduced heat (ΔT = 29.4 °C) than their 75 nm equivalents (ΔT = 26.2 °C). [107]\nPEGylated MoS2 nanosheets Size 80 nm MoS2 nanosheets produce a higher photoinduced heat (ΔT ≈ 6 °C) than their 100 nm equivalents (ΔT ≈ 4.5 °C). [15]\nPEGylated WS2 quantum dots Size Reduction of WS2 particles’ size increases their NIR absorption and thus\nimproves the photoinduced heat mediated by these nanostructures;\n[108]\nWS2 quantum dots (3 nm) have a slightly higher photothermal conversion efficiency (44.3%) than ≈ 28 nm WS2 nanosheets (40.6%, at 808 nm), and thus generate a superior photoinduced heat (ΔT = 20 °C vs. ΔT ≈ 12 °C).\nPd-PVP nanosheets Size 4.4 nm Pd-PVP nanosheets have a higher photothermal conversion efficiency\nthan 41 nm nanosheets (52 vs. 27.6%, at 808 nm), thus producing a superior photoinduced heat (≈ 50 °C vs. ≈ 37.5 °C).\n[7]\nPEGylated hollow gold-silver alloy urchin-shaped nanostructures\nSize Reduction of the hybrid structures’ size from 200 to 80 nm shifts their\nNIR absorption peak from 950 to 772 nm, thereby improving the photoinduced heat generated by these structures under 808 nm laser radiation.\n[100]\nCitrate and PEGylated Fe3O4 nanoparticles Size Increasing the size of citrate and PEG functionalized Fe3O4 nanoparticles from\n120 to 380 nm produces a red-shift in their absorption and thus improves the photoinduced heat mediated by these materials.\n[109]\nGold nanotubes Size Increasing the length of gold nanotubes from 300 to 530 nm produces a\nred-shift in their absorption;\n[110]\nGold nanotubes with a length of ≈ 370 nm display the highest absorption at 800 nm and thus were selected for cancer PTT using 800 nm radiation.\nPEGylated rGO derivatives Chemical\ntreatment\nrGO derivatives have about 3–4 times higher NIR absorption than non-reduced nGO and thereby generate a superior photoinduced heat (≈ 58 °C vs. ≈ 44 °C).\n[63]\nPEGylated rGONM Chemical\ntreatment\nrGONM has about 4.2 times higher NIR absorption than reduced nGO, thus producing a superior photoinduced heat (≈ 57 °C vs. ≈ 42 °C). [50]\nMn2+ doped PEGylated PB nanocubes Chemical treatment Mn2+ doping increases the NIR absorption of PEGylated PB nanocubes; [111]\nMn2+ doping of 15% produces the highest increment in the NIR absorption of the PB nanocubes (≈ 2-fold at 808 nm).\nGd3+ containing mesoporous PB nanoparticles Chemical treatment Incorporation of Gd3+ in PB nanoparticles produces a red-shift in their absorption towards the NIR region.\n[112]\nClustered Fe3O4 nanoparticles Assembling of nanostructures Clustered Fe3O4 nanoparticles have ≈ 3.6-fold higher NIR absorption than individual Fe3O4 nanoparticles, thus producing a superior photoinduced\nheat (≈ 51 °C vs. ≈ 42 °C).\n[41]\nNanovesicles assembled using PEG-poly(caprolactone) functionalized gold nanoparticles Assembling of nanostructures Self-assembled gold-based nanovesicles have a higher photothermal conversion efficiency than GNR (37% vs. 22%, at 808 nm), thus producing a\nsuperior photoinduced heat (ΔT ≈ 41 °C vs. ΔT = 24 °C).\n[113]\nGold-attapulgite nanocomposites Assembling of\nnanostructures\nElectrostatic assembly of gold nanospheres on the surface of attapulgite yields a composite with a photothermal conversion efficiency of 25.6% (at 808 nm).\n[114]\nPEGylated chirality sorted (6,5) CNT Sorting of\nnanomaterials\nChirality sorted (6,5) CNT have an enhanced NIR absorption, thus producing a higher photoinduced heat than non-sorted CNT (≈ 53 °C vs. ≈ 44 °C). [116]\na)poly(2-(methacryloyloxy)ethylaminocarboxymethyl)thiophene-stat-oligo(ethylene glycol) methacrylate) (poly(2TMOI-OEGMA)); b)poly[4,4-bis(2-ethylhexyl)-cyclopenta[2,1b;3,4-b’]dithiophene-2,6-diyl-alt-2,1,3-benzothiadiazole-4,7-diyl] (PCPDTBT); c)poly[4,4-bis(2-ethylhexyl)-cyclopenta[2,1-b;3,4-b’]dithiophene-2,6-diyl-alt-2,1,3-benzoselenadiazole-4,7-diyl] (PCPDTBSe).\nTable 2. Continued.\nP R O\nG R ES\nS R\nEP O\nR T\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimwileyonlinelibrary.com1700073 (14 of 20)\nto their improved photothermal efficiency (ΔT ≈ 4.5 °C vs. ΔT ≈ 6 °C).[15] Tang et al. prepared 41 and 4.4 nm sized Pd-PVP nanosheets and verified that the smallest nanomaterials show the highest photothermal conversion efficiency (52 vs. 27.6% at 808 nm).[7] Accordingly, the 4.4 nm nanosheets were able to raise the temperature to ≈ 50 °C under NIR laser irradiation, while the 41 nm nanomaterials only elevated it to ≈ 37.5 °C.\nOn the other hand, the absorption spectrum of some nanomaterials can be fine-tuned towards the NIR region by increasing nanomaterials’ size. Peng et al. observed that by augmenting the size of citrate and PEG functionalized Fe3O4 nanoparticles from 120 to 380nm, a red-shift in their absorption spectrum is attained.[109] Due to this phenomenon, the 380 nm sized Fe3O4 nanoparticles exhibited an improved NIR absorption and mediated the highest temperature increase under NIR laser irradiation when compared to their equivalents with smaller dimensions (120, 240 and 300 nm). Ye et al. verified that by increasing the length of gold nanotubes from 300 to 530 nm, a shift in their absorption towards the NIR region is also observed.[110] In this case, the gold nanotubes with a length of approximately 370 nm were considered optimal systems since these showed the highest absorption at 800 nm."
    }, {
      "heading" : "4.3. Chemical Treatment of Nanomaterials",
      "text" : "The reduction of nGO is the most employed strategy to enhance its NIR absorption by restoring the aromatic lattice of this nanomaterial.[50,63] Yang et al. demonstrated that the reduction of GO derivatives with hydrazine hydrate produces reduced GO (rGO)-based nanomaterials that have a 3–4 times higher NIR absorption than nGO, leading to the production of a higher photoinduced heat (≈ 58 °C vs. ≈ 44 °C).[63] Akhavan and Ghaderi reported that the photodegradation and subsequent reduction of nGO yields reduced graphene oxide nanomesh (rGONM) with a NIR absorption ≈ 4.2 times higher than the reduced nGO.[50] In this way, the rGONM induced, under NIR laser irradiation, an increase in temperature up to ≈ 57 °C, while in the same conditions the reduced nGO only elevated the temperature to ≈ 42 °C.\nThe photothermal capacity of PB nanostructures has been improved by doping these materials with Mn2+and Gd3+.[111,112] PEGylated PB nanocubes doped with 15% Mn2+ displayed an almost 2-fold increased NIR absorption that lead to an improved temperature variation (ΔT ≈ 10 °C), upon material irradiation.[111]"
    }, {
      "heading" : "4.4. Assembling of Nanostructures",
      "text" : "In some cases, the assembly of nanostructures into clusters or vesicles can be used to provoke a red-shift in their absorption profile towards the NIR region and, consequently, enhance their photothermal capacity.[41,113,114] Shen et al. prepared clusters of Fe3O4 nanoparticles that display a ≈ 3.6-fold higher NIR absorption than the individual Fe3O4 nanoparticles.[41] The clustered Fe3O4 nanoparticles elicited the highest hyperthermia (≈ 56 °C vs. ≈ 50 °C) and the most potent antitumoral effect upon NIR laser irradiation due to their superior NIR absorption. In\nanother work, Huang et al. synthesized PEG-poly(caprolactone) functionalized gold nanoparticles, which did not display any NIR absorption, and assembled them into gold-based nanovesicles.[113] The assembled nanovesicles presented a high NIR absorption and a photothermal conversion efficiency of 37%, which was higher than that of GNR (22% at 808 nm). Owing to their superior photothermal efficiency, the assembled nanovesicles increased the temperature of the tumors by ≈ 18 °C and mediated their eradication under NIR laser irradiation. In the same conditions, the GNR were only able to induce a hyperthermia of ≈ 10 °C and a reduction of the tumor growth, thus revealing the advantage of the assembly of nanovesicles for the desired biomedical application."
    }, {
      "heading" : "4.5. Sorting of Nanomaterials",
      "text" : "The commonly available methods to produce CNT (e.g. highpressure carbon monoxide conversion) yield a mixture of nanostructures with different chiralities, some of which have a low NIR absorption. For this reason, sorting CNT with defined chirality is a successful strategy for improving the photothermal performance of these materials.[115,116] Antaris and co-workers demonstrated that PEGylated chirality sorted (6,5) CNT have a higher NIR absorption than non-sorted CNT.[116] Consequently, the sorted CNT were able to mediate under NIR laser irradiation a hyperthermia to ≈ 51 °C and tumor eradication for 3 in 4 mice. For mice treated with non-sorted CNT, tumor growth inhibition was not observed since these nanomaterials only induced a hyperthermia to ≈ 44 °C due to their inferior optical properties."
    }, {
      "heading" : "5. Optimization of the Parameters Related to the Laser Light for Improving the PTT Mediated by Nanomaterials",
      "text" : "The wavelength, power density and onset of the irradiation are important players in nanomaterials’ mediated PTT since their correct modulation is crucial for avoiding off-target heating of healthy tissues and also to ensure that an appropriate hyperthermia is achieved during the therapeutic procedure.[93,117] Therefore, various strategies have been applied to improve the outcome of this therapeutic modality by performing the adjustment of these laser light related parameters (Figure 4). The exposition of multiple sites to NIR light and application of multiple irradiation sessions are other strategies that have been explored to improve nanomaterials’ mediated PTT (summarized in Table 3)."
    }, {
      "heading" : "5.1. Wavelength",
      "text" : "As discussed in section 2, the application of NIR light is crucial in cancer PTT. However, the absorption displayed by water at wavelengths above 900 nm demands additional precautions when tissues are exposed to radiation with a wavelength superior to 900 nm in order to avoid off-target heating.[28,118,119]\nwww.advhealthmat.de\nAdv. Healthcare Mater. 2017, 1700073\nwww.advancedsciencenews.com\nP R O G R ES S R EP O R T\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim wileyonlinelibrary.com (15 of 20) 1700073\nIn this way, the selection of the appropriate wavelength of the NIR radiation can be pursued to improve nanomaterials’ mediated PTT. Xu et al. verified that despite PEGylated CsxWO3 nanorods having a higher absorbance at 980 nm than at 915 nm, nanostructures irradiation at 915 nm is advantageous over their irradiation at a higher wavelength, since a higher penetration and lower off-target heating are reached.[119] Tian and co-workers observed that although PVP coated Rb0.27WO3 nanorods display a higher absorption at 980 nm than at 808 nm, the irradiation of the nanorods with the lower wavelength light can produce a higher temperature variation, since the 980 nm light has a lower depth penetration.[120]"
    }, {
      "heading" : "5.2. Power Density",
      "text" : "The power density (total energy per second delivered into a specific area) of the NIR irradiation can be adjusted to improve the outcome of the PTT. Yang et al. assessed in vivo the PTT capacity of poly(vinyl alcohol) (PVA) coated PPy nanoparticles using different power densities.[117] When nanoparticles were irradiated at a power density of 0.1 W cm−2, these mediated a hyperthermia to ≈ 42 °C that led to tumor growth reduction. In contrast, when a power density of 0.25 and 0.5 W cm−2 was used, a hyperthermia to about 55 and 60 °C was attained, leading to the elimination of mice’s tumors. Guo et al. verified that (NH4)xWO3 nanocubes mediate an increment of ≈ 45 °C in\ntumor’s temperature when these are irradiated at a power density of 1 W cm−2.[93] This hyperthermic effect was responsible for a reduction in the volume of the tumors and also for the inhibition of lung metastases. On the other hand, when PTT was performed at a power density of 0.5 W cm−2, a weaker therapeutic effect was obtained, which is consistent with the lower hyperthermia attained (ΔT ≈ 33 °C)."
    }, {
      "heading" : "5.3. Irradiation Onset",
      "text" : "The therapeutic effect achieved through nanomaterials’ mediated PTT depends on the ON/OFF cycles of the radiation.[9,10] Thereby, the hyperthermia and the therapeutic outcome can be maximized by synchronizing the onset of the laser irradiation with the maximum accumulation of the nanomaterials within the tumor. This strategy was explored by Sharker et al., which verified that hyaluronic acid (HA) functionalized WO3 nanoparticles display a high tumor accumulation at 8 h postadministration.[9] Accordingly, these researchers noticed that the highest hyperthermia (50 °C) is obtained when the onset of the NIR laser irradiation starts on this time point (at 8 h postinjection). In another work, Zhou et al. verified that PVP coated CuS nanodots hit their maximum tumor accumulation (≈ 3.6% ID g−1) at 2 h post-injection and PTT performed at this time point leads to tumor eradication by using only two minutes of NIR laser irradiation.[14]\nwww.advhealthmat.de\nAdv. Healthcare Mater. 2017, 1700073\nwww.advancedsciencenews.com\nFigure 4. Schematic representation of the parameters related to the laser light that influence the PTT mediated by nanomaterials. In the wavelength panel, the bars represent the absorption of different bio-components and the color intensity is proportional to their absorption at that specific wavelength. The data from the wavelength panel were extrapolated from Vogel et al.[28]\nP R O\nG R ES\nS R\nEP O\nR T\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimwileyonlinelibrary.com1700073 (16 of 20)"
    }, {
      "heading" : "5.4. Irradiated Site",
      "text" : "The therapeutic effect mediated by nanomaterials can also be improved by exposing simultaneously the tumor zone and metastatic sites to NIR light. This strategy was explored by Liang et al., who verified that intratumorally injected PEGylated CNT remain in the tumor tissue and also become accumulated in the tumor-adjacent lymph node.[121] These zones were then exposed to NIR light and nanomaterials increased the temperature of the tumor and the lymph node to about 55 and 47 °C, respectively. Such effect was responsible for tumor eradication in 6 out of 7 mice.[121] In stark contrast, mice irradiated only in the tumor had a poor survival rate, since multiple metastases were observed in the lungs. Furthermore, it should also be highlighted that to compensate for the lower accumulation of the CNT in the lymph node (and also due to its deeper localization), this site was irradiated at a higher power density (0.8 W cm−2 for lymph node vs. 0.5 W cm−2 for tumor). Thus, the optimization of the irradiation site and the power density are fundamental to achieve an appropriate hyperthermia at the target sites in order for an improved photothermal effect be attained.\nwww.advhealthmat.de\nAdv. Healthcare Mater. 2017, 1700073\nwww.advancedsciencenews.com\nTable 3. Strategies based on the optimization of the parameters related to the laser light.\nNanomaterial Optimization Result Ref.\nPEGylated CsxWO3 nanorods Wavelength Even though PEGylated CsxWO3 nanorods have a higher absorbance at 980 nm than at\n915 nm, the use of 915 nm light is beneficial since the 980 nm radiation has less penetration and induces a higher off-target heating.\n[119]\nPVP coated Rb0.27WO3 nanorods Wavelength Even though PVP coated Rb0.27WO3 have a higher absorption at 980 nm than at 808 nm,\nthe application of 808 nm light to irradiate the nanorods can produce a higher temperature variation than 980 nm radiation due to its higher penetration.\n[120]\nPVA coated PPy nanoparticles Power density Nanomaterials’ mediated PTT at a power density of 0.25 and 0.5 W cm−2 produces a\nhyperthermia to about 55 and 60 °C, resulting in the elimination of mice’s tumors; [117]\nPTT at a power density of 0.1 W cm−2 mediates a hyperthermia to ≈ 42 °C, leading to a reduction of the tumor growth.\n(NH4)xWO3 nanocubes Power density Nanomaterials’ mediated PTT at a power density of 1 W cm−2 (every three days during\n9 days) mediates a higher hyperthermia (ΔT ≈ 45 °C) and a better therapeutic outcome than PTT at 0.5 W cm−2 (ΔT ≈ 33 °C).\n[93]\nIrradiation sessions\nC18-PMH-mPEG coated CNT Power density Irradiation of tumor zone and tumor-adjacent lymph node results in an improved\ntherapeutic effect;\n[121]\nIrradiation sites The lymph node was irradiated at a higher power density due to its deeper location and\ndue to CNT lower accumulation at this site (lymph node: 0.8 W cm−2; tumor: 0.5 W cm−2).\nChitosan-pluronic F-68 conjugates encapsulating GNR\nIrradiation sessions Irradiation of the tumor zone at 24 and 48 h post-injection of nanoparticles leads to\ntumor eradication.\n[11]\nRBC membrane coated PVP-gold nanocages Irradiation sessions Laser irradiation once a day during 19 days elicits a potent therapeutic effect. [68]\nCD44 targeted PEGylated gold nanostars Irradiation sessions Laser irradiation every two days during 14 days elicits a potent therapeutic effect. [72]\nPEGylated WO2.9 nanorods Irradiation sessions Laser irradiation every two days during 14 days allows the elimination of mice’s tumors\nat a low power density.\n[16]\nDSPE-PEG-CREKA functionalized CNT Irradiation sessions Irradiation of the tumor zone at 10 min after administration of DSPE-PEG-CREKA coated\nCNT (fibrin targeted CNT) enhances their tumor accumulation by about 3.8-fold;\n[122]\nIrradiation of the tumor zone at 10 min after administration of DSPE-PEG coated CNT improves their tumor accumulation by about 2.6-fold;\nMice administered with these materials were irradiated multiple times (at 10 min and on day 3, 6 and 9 post-injection) to take advantage of these phenomena.\nHA functionalized WO3 nanoparticles Irradiation onset Irradiation of the tumor zone at 8 h post-injection of HA-WO3 nanoparticles produces the highest hyperthermia (50 °C). [9]\nPVP coated CuS nanodots Irradiation onset PVP coated CuS nanodots achieve their maximum tumor accumulation (≈ 3.6% ID g−1) at 2 h post-injection and PTT at this time point leads to tumor eradication with\nonly 2 minutes of NIR laser irradiation.\n[14]\nHA-g-PEG coated PB hollow nanocubes Irradiation onset HA-g-PEG coated PB hollow nanocubes achieve their maximum tumor accumulation at 24 h post-injection and PTT at this time point leads to a hyperthermia to 53 °C. [73]\nPEGylated Cu2–xSe nanoparticles Irradiation onset PEGylated Cu2–xSe nanoparticles achieve their maximum tumor accumulation\n(4.4% ID g−1) at 12 h post-injection and PTT at this time point leads to tumor eradication.\n[84]\nGSH functionalized MoS2 nanodots Irradiation onset GSH functionalized MoS2 nanodots achieve their maximum tumor accumulation (≈ 5% ID g−1) at 4 h post-injection and PTT at this time point leads to tumor eradication. [152]\nP R O G R ES S R EP O R T\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim wileyonlinelibrary.com (17 of 20) 1700073"
    }, {
      "heading" : "5.5. Number of Irradiation Sessions",
      "text" : "The application of multiple irradiation sessions is another approach that has been used for achieving better photothermal effects. Choi and co-workers observed that chitosan-pluronic F-68 conjugates encapsulating GNR are able to mediate tumor eradication with two laser irradiation sessions (at 24 and 48 h post-injection) while the application of one irradiation session (at 24 h post-injection) only resulted in a reduction of the tumor growth.[11] In another work, Zhou and co-workers noticed that PEGylated WO2.9 nanorods could mediate the elimination of mice’s tumors by using a low power density (0.35 W cm−2) through the application of multiple irradiation sessions (every two days during 14 days).[16] Recently, Zhang et al. performed multiple irradiation sessions after administration of DSPE-PEG coated CNT (at 10 min and on day 3, 6 and 9 post-injection), and they verified that the application of NIR radiation at 10 min post-injection improves nanomaterials’ tumor accumulation by about 2.6-fold, presumably due to an enhanced tumor vasculature perfusion and permeability that is promoted by the hyperthermia attained (hyperthermia enhanced EPR effect).[122] In the same study, authors also explored DSPE-PEG-(Cys-Arg-GluLys-Ala) (CREKA) functionalized CNT, which bind to fibrin, and they perceived that after administration of the targeted CNT and application of the first irradiation session (at 10 min post-injection), the hyperthermia produced greatly increases the amount of fibrin deposited in the tumor zone and such is responsible for a ≈ 3.8-fold increase in the tumor accumulation of the functionalized CNT."
    }, {
      "heading" : "6. Conclusion and Outlook",
      "text" : "In this progress report, we covered the recent strategies, reported in the literature, used for improving the therapeutic outcome of the PTT mediated by gold, carbon, copper, molybdenum, tungsten, iron, palladium and conjugated polymers based nanomaterials.\nThe application of PEG-based coatings and the inclusion of targeting ligands on nanomaterials’ surface improved their tumor-homing capacity and hence their PTT capacity. Such data emphasizes the importance of pursuing the appropriate surface composition for each type of photothermal agent through the optimization of the PEG corona composition, targeting ligand density and spacer-arm length, or through the application of alternative coatings, such as those based on PVP or RCB/ macrophages’ membranes. Moreover, reports describing the application of targeted Mo, Pd, PPy and PEDOT based nanomaterials in cancer PTT were not found, which should motivate the development of functionalization strategies for these types of nanostructures. Nanomaterials’ size, shape, and charge were not systematically optimized for each type of photothermal agent. In the particular case of the size and shape, such could be attributed to the fact that variations in these characteristics have a direct impact on nanomaterials’ photothermal efficiency. Regarding nanomaterials’ charge, the utilization of zwitterionic-based approaches should be further explored since it holds a great potential for improving the biodistribution of the nanostructures.\nSo far, several strategies have also been applied to augment the capacity of nanomaterials to generate heat under NIR laser irradiation and thus enhance their PTT potential. To accomplish that, new nanomaterials have been produced, being this the most straightforward strategy. Other approaches are currently under investigation, comprising the optimization of nanostructures’ size, chemical treatment, sorting and assembling of nanostructures. However, in some of the reports describing these strategies, the photothermal efficacy of the nanostructures was only assessed in vitro or in vivo after intratumoral injection, which should motivate researchers to evaluate nanomaterials’ photoablation capacity after systemic administration (e.g. intravenous administration) in future works. Moreover, some of these nanomaterials were not engineered to present colloidal stability, tumor-homing capacity or resistance to protein adsorption and thus, the improvement of these attributes will surely augment their PTT potential.\nThe optimization of the parameters related to the laser light can also improve the outcome of nanomaterials’ mediated PTT. The strategies applied, until now, have been focused on the adjustment of the wavelength, power density, irradiated sites, number of irradiation sessions and on the optimization of the irradiation onset. However, these strategies were not frequently explored in the literature and were mostly applied for W-based nanostructures and to a lesser extent to others such as CNT or gold-based nanomaterials. Moreover, this type of laser-sided optimizations does not imply modifications in the attributes of the nanomaterials and, for this reason, its implementation should be simple and further explored in cancer PTT.\nFinally, excluding the influence of the differences between the tumor models (e.g. type and size of tumor) of the reports herein analyzed (Table S1), it seems that for the bulk part of the cases and independently of the type of strategy applied to improve the PTT mediated by nanomaterials, achieving a hyperthermia to 57 °C ensures the photoablation of the tumors. Hence, the development of new strategies that endow nanomaterials with this capability or the optimization and combination of the existing ones will surely give a major contribution for their application in cancer PTT.\nSupporting Information Supporting Information is available from the Wiley Online Library or from the author."
    }, {
      "heading" : "Acknowledgements",
      "text" : "The authors acknowledge Dr. Ricardo O. Louro for his comments and suggestions during the preparation of the manuscript. This work was supported by FEDER funds through the POCI – COMPETE 2020 – Operational Programme Competitiveness and Internationalisation in Axis I – Strengthening research, technological development and innovation (Project POCI-01-0145-FEDER-007491) and National Funds by FCT – Foundation for Science and Technology (Project UID/Multi /00709/2013). Duarte de Melo-Diogo and André F. Moreira acknowledge individual PhD fellowships from FCT (SFRH/BD/103506/2014 and SFRH/BD/109482/2015).\nReceived: January 18, 2017 Revised: February 16, 2017\nPublished online:\nwww.advhealthmat.de\nAdv. Healthcare Mater. 2017, 1700073\nwww.advancedsciencenews.com\nP R O\nG R ES\nS R\nEP O\nR T\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimwileyonlinelibrary.com1700073 (18 of 20)\n[1] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, D. Forman, Ca-Cancer J. Clin. 2011, 61, 69. [2] N. Cihoric, A. Tsikkinis, G. van Rhoon, H. Crezee, D. M. Aebersold, S. Bodis, M. Beck, J. Nadobny, V. Budach, P. Wust, P. Ghadjar, Int. J. Hyperthermia 2015, 31, 609. [3] C. L. K. Pang, Hyperthermia in Oncology, CRC Press, Boca Raton, Florida, 2015. [4] K. F. Chu, D. E. Dupuy, Nat. Rev. Cancer 2014, 14, 199. [5] G. Baronzio, M. Jackson, D. Lee, A. Szász, Conference Papers in\nMedicine 2013, 2013. [6] a) S. Balivada, R. S. Rachakatla, H. Wang, T. N. Samarakoon,\nR. K. Dani, M. Pyle, F. O. Kroh, B. Walker, X. Leaym, O. B. Koper, BMC Cancer 2010, 10, 119; b) D. P. O’Neal, L. R. Hirsch, N. J. Halas, J. D. Payne, J. L. West, Cancer Lett. 2004, 209, 171. [7] S. Tang, M. Chen, N. Zheng, Small 2014, 10, 3139. [8] L. Cheng, K. Yang, Q. Chen, Z. Liu, ACS Nano 2012, 6, 5605. [9] S. M. Sharker, S. M. Kim, J. E. Lee, K. H. Choi, G. Shin, S. Lee,\nK. D. Lee, J. H. Jeong, H. Lee, S. Y. Park, J. Controlled Release 2015, 217, 211. [10] B. Li, Q. Wang, R. Zou, X. Liu, K. Xu, W. Li, J. Hu, Nanoscale 2014, 6, 3274. [11] W. I. Choi, J.-Y. Kim, C. Kang, C. C. Byeon, Y. H. Kim, G. Tae, ACS Nano 2011, 5, 1995. [12] X. Liu, H. Tao, K. Yang, S. Zhang, S.-T. Lee, Z. Liu, Biomaterials 2011, 32, 144. [13] K. Yang, S. Zhang, G. Zhang, X. Sun, S.-T. Lee, Z. Liu, Nano Lett. 2010, 10, 3318. [14] M. Zhou, J. Li, S. Liang, A. K. Sood, D. Liang, C. Li, ACS Nano 2015, 9, 7085. [15] S. Wang, K. Li, Y. Chen, H. Chen, M. Ma, J. Feng, Q. Zhao, J. Shi, Biomaterials 2015, 39, 206. [16] Z. Zhou, B. Kong, C. Yu, X. Shi, M. Wang, W. Liu, Y. Sun, Y. Zhang, H. Yang, S. Yang, Sci. Rep. 2014, 4, 3653. [17] L. Cheng, H. Gong, W. Zhu, J. Liu, X. Wang, G. Liu, Z. Liu, Biomaterials 2014, 35, 9844. [18] J. Yang, J. Choi, D. Bang, E. Kim, E. K. Lim, H. Park, J. S. Suh, K. Lee, K. H. Yoo, E. K. Kim, Angew. Chem., Int. Ed. 2011, 123, 461. [19] B. Mensel, C. Weigel, N. Hosten, in Minimally Invasive Tumor Therapies, (Ed: C. Stroszczynski), Springer Berlin Heidelberg, Berlin, Heidelberg 2006, p. 69. [20] D. Huo, J. He, H. Li, A. J. Huang, H. Y. Zhao, Y. Ding, Z. Y. Zhou, Y. Hu, Biomaterials 2014, 35, 9155. [21] B.-P. Jiang, L. Zhang, Y. Zhu, X.-C. Shen, S.-C. Ji, X.-Y. Tan, L. Cheng, H. Liang, J. Mater. Chem. B 2015, 3, 3767. [22] J. Kim, E. Lee, Y. Hong, B. Kim, M. Ku, D. Heo, J. Choi, J. Na, J. You, S. Haam, Adv. Funct. Mater. 2015, 25, 2260. [23] J. M. Stern, V. V. K. Solomonov, E. Sazykina, J. A. Schwartz, S. C. Gad, G. P. Goodrich, Int. J. Toxicol. 2016, 35, 38. [24] S. K. Hobbs, W. L. Monsky, F. Yuan, W. G. Roberts, L. Griffith, V. P. Torchilin, R. K. Jain, Proc. Natl. Acad. Sci. USA 1998, 95, 4607. [25] E. Blanco, H. Shen, M. Ferrari, Nat. Biotechnol. 2015, 33, 941. [26] L. Cheng, J. Liu, X. Gu, H. Gong, X. Shi, T. Liu, C. Wang, X. Wang,\nG. Liu, H. Xing, Adv. Mater. 2014, 26, 1886. [27] M. J. Ernsting, M. Murakami, A. Roy, S. D. Li, J. Control. Release\n2013, 172, 782. [28] A. Vogel, V. Venugopalan, Chem. Rev. 2003, 103, 577. [29] a) S. Stolik, J. Delgado, A. Perez, L. Anasagasti, J. Photochem.\nPhotobiol., B 2000, 57, 90; b) E. C. Dreaden, M. A. Mackey, X. Huang, B. Kang, M. A. El-Sayed, Chem. Soc. Rev. 2011, 40, 3391; c) D. E. Hudson, D. O. Hudson, J. M. Wininger, B. D. Richardson, Photomed. Laser Surg. 2013, 31, 163; d) A. M. Smith, M. C. Mancini, S. Nie, Nat. Nanotechnol. 2009, 4, 710. [30] M. Zhou, S. Song, J. Zhao, M. Tian, C. Li, J. Mater. Chem. B 2015, 3, 8939.\n[31] Y. Wang, K. C. Black, H. Luehmann, W. Li, Y. Zhang, X. Cai, D. Wan, S.-Y. Liu, M. Li, P. Kim, ACS Nano 2013, 7, 2068. [32] a) D. R. Dias, A. F. Moreira, I. J. Correia, J. Mater. Chem. B 2016, 4, 7630; b) G. von Maltzahn, J.-H. Park, A. Agrawal, N. K. Bandaru, S. K. Das, M. J. Sailor, S. N. Bhatia, Cancer Res. 2009, 69, 3892. [33] M. Xuan, J. Shao, L. Dai, J. Li, Q. He, ACS Appl. Mater. Interfaces 2016, 8, 9610. [34] S. Wang, Z. Teng, P. Huang, D. Liu, Y. Liu, Y. Tian, J. Sun, Y. Li, H. Ju, X. Chen, Small 2015, 11, 1801. [35] a) J. Feng, L. Chen, Y. Xia, J. Xing, Z. Li, Q. Qian, Y. Wang, A. Wu, L. Zeng, Y. Zhou, ACS Biomaterials Science & Engineering 2017, doi: 10.1021/acsbiomaterials.7b00021; b) X. Chen, Z. Liu, S. G. Parker, X. Zhang, J. J. Gooding, Y. Ru, Y. Liu, Y. Zhou, ACS Appl. Mater. Interfaces 2016, 8, 15857. [36] J. Mou, P. Li, C. Liu, H. Xu, L. Song, J. Wang, K. Zhang, Y. Chen, J. Shi, H. Chen, Small 2015, 11, 2275. [37] M. Zhou, R. Zhang, M. Huang, W. Lu, S. Song, M. P. Melancon, M. Tian, D. Liang, C. Li, J. Am. Chem. Soc. 2010, 132, 15351. [38] C. M. Hessel, V. P. Pattani, M. Rasch, M. G. Panthani, B. Koo, J. W. Tunnell, B. A. Korgel, Nano Lett. 2011, 11, 2560. [39] S.-M. Zhou, D.-K. Ma, S.-H. Zhang, W. Wang, W. Chen, S.-M. Huang, K. Yu, Nanoscale 2016, 8, 1374. [40] T. Bao, W. Yin, X. Zheng, X. Zhang, J. Yu, X. Dong, Y. Yong, F. Gao, L. Yan, Z. Gu, Biomaterials 2016, 76, 11. [41] S. Shen, S. Wang, R. Zheng, X. Zhu, X. Jiang, D. Fu, W. Yang, Biomaterials 2015, 39, 67. [42] K. Yang, G. Yang, L. Chen, L. Cheng, L. Wang, C. Ge, Z. Liu, Biomaterials 2015, 38, 1. [43] T. Fu, Y. Chen, J. Hao, X. Wang, G. Liu, Y. Li, Z. Liu, L. Cheng, Nanoscale 2015, 7, 20757. [44] S. Shi, Y. Huang, X. Chen, J. Weng, N. Zheng, ACS Appl. Mater. Interfaces 2015, 7, 14369. [45] M. Chen, X. Fang, S. Tang, N. Zheng, Chem. Commun. 2012, 48, 8934. [46] J. Geng, C. Sun, J. Liu, L. D. Liao, Y. Yuan, N. Thakor, J. Wang, B. Liu, Small 2015, 11, 1603. [47] C. M. MacNeill, E. G. Graham, N. H. Levi Polyachenko, J. Polym. Sci., Part A: Polym. Chem. 2014, 52, 1622. [48] a) H. S. Choi, W. Liu, P. Misra, E. Tanaka, J. P. Zimmer, B. I. Ipe, M. G. Bawendi, J. V. Frangioni, Nat. Biotechnol. 2007, 25, 1165; b) C. Zhou, M. Long, Y. Qin, X. Sun, J. Zheng, Angew. Chem., Int. Ed. 2011, 123, 3226. [49] a) D. Liu, A. Mori, L. Huang, Biochim. Biophys. Acta Biomembr. 1992, 1104, 95; b) G. Sonavane, K. Tomoda, K. Makino, Colloids Surf., B 2008, 66, 274. [50] O. Akhavan, E. Ghaderi, Small 2013, 9, 3593. [51] a) K. Huang, H. Ma, J. Liu, S. Huo, A. Kumar, T. Wei, X. Zhang,\nS. Jin, Y. Gan, P. C. Wang, S. He, X. Zhang, X.-J. Liang, ACS Nano 2012, 6, 4483; b) H. Cabral, Y. Matsumoto, K. Mizuno, Q. Chen, M. Murakami, M. Kimura, Y. Terada, M. Kano, K. Miyazono, M. Uesaka, N. Nishiyama, K. Kataoka, Nat. Nano 2011, 6, 815; c) S. D. Perrault, C. Walkey, T. Jennings, H. C. Fischer, W. C. W. Chan, Nano Lett. 2009, 9, 1909. [52] H. Wang, R. Zhao, Y. Li, H. Liu, F. Li, Y. Zhao, G. Nie, Nanomedicine (N. Y., NY, U. S.) 2016, 12, 439. [53] H. Zhang, C. Peng, J. Yang, M. Lv, R. Liu, D. He, C. Fan, Q. Huang, ACS Appl. Mater. Interfaces 2013, 5, 1761. [54] a) K. C. Black, Y. Wang, H. P. Luehmann, X. Cai, W. Xing, B. Pang, Y. Zhao, C. S. Cutler, L. V. Wang, Y. Liu, ACS Nano 2014, 8, 4385; b) M. Janát-Amsbury, A. Ray, C. Peterson, H. Ghandehari, Eur. J. Pharm. Biopharm. 2011, 77, 417; c) X. Huang, X. Teng, D. Chen, F. Tang, J. He, Biomaterials 2010, 31, 438. [55] S. Tang, X. Huang, N. Zheng, Chem. Commun. 2011, 47, 3948. [56] Z.-G. Yue, W. Wei, P.-P. Lv, H. Yue, L.-Y. Wang, Z.-G. Su, G.-H. Ma,\nBiomacromolecules 2011, 12, 2440.\nwww.advhealthmat.de\nAdv. Healthcare Mater. 2017, 1700073\nwww.advancedsciencenews.com\nP R O G R ES S R EP O R T\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim wileyonlinelibrary.com (19 of 20) 1700073\n[57] S. Riedl, D. Zweytick, K. Lohner, Chem. Phys. Lipids 2011, 164, 766. [58] a) T. S. Levchenko, R. Rammohan, A. N. Lukyanov, K. R. Whiteman,\nV. P. Torchilin, Int. J. Pharm. 2002, 240, 95; b) K. Xiao, Y. Li, J. Luo, J. S. Lee, W. Xiao, A. M. Gonik, R. G. Agarwal, K. S. Lam, Biomaterials 2011, 32, 3435. [59] a) A. Gessner, A. Lieske, B. R. Paulke, R. H. Müller, Eur. J. Pharm. Biopharm. 2002, 54, 165; b) A. Gessner, A. Lieske, B. R. Paulke, R. H. Müller, J. Biomed. Mater. Res., Part A 2003, 65, 319; c) S. Tenzer, D. Docter, J. Kuharev, A. Musyanovych, V. Fetz, R. Hecht, F. Schlenk, D. Fischer, K. Kiouptsi, C. Reinhardt, Nat. Nanotechnol. 2013, 8, 772. [60] K. Knop, R. Hoogenboom, D. Fischer, U. S. Schubert, Angew. Chem., Int. Ed. 2010, 49, 6288. [61] a) C. D. Walkey, J. B. Olsen, H. Guo, A. Emili, W. C. Chan, J. Am. Chem. Soc. 2012, 134, 2139; b) Q. Yang, S. W. Jones, C. L. Parker, W. C. Zamboni, J. E. Bear, S. K. Lai, Mol. Pharmaceutics 2014, 11, 1250. [62] J. T. Robinson, G. Hong, Y. Liang, B. Zhang, O. K. Yaghi, H. Dai, J. Am. Chem. Soc. 2012, 134, 10664. [63] K. Yang, J. Wan, S. Zhang, B. Tian, Y. Zhang, Z. Liu, Biomaterials 2012, 33, 2206. [64] G. Song, J. Hao, C. Liang, T. Liu, M. Gao, L. Cheng, J. Hu, Z. Liu, Angew. Chem., Int. Ed. 2015, 55, 2122. [65] X. Liang, Y. Li, X. Li, L. Jing, Z. Deng, X. Yue, C. Li, Z. Dai, Adv. Funct. Mater. 2015, 25, 1451. [66] a) J. L. Perry, K. G. Reuter, M. P. Kai, K. P. Herlihy, S. W. Jones, J. C. Luft, M. Napier, J. E. Bear, J. M. DeSimone, Nano Lett 2012, 12, 5304; b) B. Pelaz, P. Del Pino, P. Maffre, R. Hartmann, M. Gallego, S. Rivera-Fernandez, J. M. de la Fuente, G. U. Nienhaus, W. J. Parak, ACS Nano 2015, 9, 6996. [67] a) Y. Li, R. Liu, Y. Shi, Z. Zhang, X. Zhang, Theranostics 2015, 5, 583; b) A. S. A. Lila, K. Nawata, T. Shimizu, T. Ishida, H. Kiwada, Int. J. Pharm. 2013, 456, 235; c) M. Bauer, C. Lautenschlaeger, K. Kempe, L. Tauhardt, U. S. Schubert, D. Fischer, Macromol. Biosci. 2012, 12, 986; d) V. M. Gaspar, P. Baril, E. C. Costa, D. de Melo-Diogo, F. Foucher, J. A. Queiroz, F. Sousa, C. Pichon, I. J. Correia, J. Control. Release 2015, 213, 175; e) P. H. Kierstead, H. Okochi, V. J. Venditto, T. C. Chuong, S. Kivimae, J. M. Fréchet, F. C. Szoka, J. Control. Release 2015, 213, 1. [68] J.-G. Piao, L. Wang, F. Gao, Y.-Z. You, Y. Xiong, L. Yang, ACS Nano 2014, 8, 10414. [69] X. Ren, R. Zheng, X. Fang, X. Wang, X. Zhang, W. Yang, X. Sha, Biomaterials 2016, 92, 13. [70] L. F. Neves, J. J. Krais, B. D. Van Rite, R. Ramesh, D. E. Resasco, R. G. Harrison, Nanotechnology 2013, 24, 375104. [71] J. H. Lee, A. Sahu, C. Jang, G. Tae, J. Control. Release 2015, 209, 219. [72] S. Liang, C. Li, C. Zhang, Y. Chen, L. Xu, C. Bao, X. Wang,\nTheranostics 2015, 5, 970. [73] L. Jing, S. Shao, Y. Wang, Y. Yang, X. Yue, Z. Dai, Theranostics 2016,\n6, 40. [74] T. Lee, D. Bang, Y. Park, S. H. Kim, J. Choi, J. Park, D. Kim, E. Kim,\nJ. S. Suh, Y. M. Huh, Adv. Healthcare Mater. 2014, 3, 1408. [75] H. Jo, H. Youn, S. Lee, C. Ban, J. Mater. Chem. B 2014, 2, 4862. [76] C. Jang, J. H. Lee, A. Sahu, G. Tae, Nanoscale 2015, 7, 18584. [77] D. Banerjee, R. Harfouche, S. Sengupta, Vasc. Cell 2011, 3, 3. [78] D. Yang, L. Feng, C. A. Dougherty, K. E. Luker, D. Chen,\nM. A. Cauble, M. M. B. Holl, G. D. Luker, B. D. Ross, Z. Liu, Biomaterials 2016, 104, 361. [79] W. Tao, J. Zhang, X. Zeng, D. Liu, G. Liu, X. Zhu, Y. Liu, Q. Yu, L. Huang, L. Mei, Adv. Healthcare Mater. 2015, 4, 1203. [80] A. Salvati, A. S. Pitek, M. P. Monopoli, K. Prapainop, F. B. Bombelli, D. R. Hristov, P. M. Kelly, C. Åberg, E. Mahon, K. A. Dawson, Nat. Nanotechnol. 2013, 8, 137. [81] B.-X. Zhao, Y. Zhao, Y. Huang, L.-M. Luo, P. Song, X. Wang, S. Chen, K.-F. Yu, X. Zhang, Q. Zhang, Biomaterials 2012, 33, 2508.\n[82] Q. Dai, C. Walkey, W. C. W. Chan, Angew. Chem., Int. Ed. 2014, 53, 5093. [83] Z. Liu, W. Cai, L. He, N. Nakayama, K. Chen, X. Sun, X. Chen, H. Dai, Nat. Nanotechnol. 2007, 2, 47. [84] S. Zhang, C. Sun, J. Zeng, Q. Sun, G. Wang, Y. Wang, Y. Wu, S. Dou, M. Gao, Z. Li, Adv. Mater. 2016, 28, 8927. [85] Q. Tian, F. Jiang, R. Zou, Q. Liu, Z. Chen, M. Zhu, S. Yang, J. Wang, J. Wang, J. Hu, ACS Nano 2011, 5, 9761. [86] J.-W. Xiao, S.-X. Fan, F. Wang, L.-D. Sun, X.-Y. Zheng, C.-H. Yan, Nanoscale 2014, 6, 4345. [87] C. Ayala-Orozco, C. Urban, M. W. Knight, A. S. Urban, O. Neumann, S. W. Bishnoi, S. Mukherjee, A. M. Goodman, H. Charron, T. Mitchell, M. Shea, R. Roy, S. Nanda, R. Schiff, N. J. Halas, A. Joshi, ACS Nano 2014, 8, 6372. [88] J. Zeng, D. Goldfeld, Y. Xia, Angew. Chem., Int. Ed. 2013, 52, 4169. [89] P. Huang, P. Rong, J. Lin, W. Li, X. Yan, M. G. Zhang, L. Nie, G. Niu, J. Lu, W. Wang, X. Chen, J. Am. Chem. Soc. 2014, 136, 8307. [90] J. R. Cole, N. A. Mirin, M. W. Knight, G. P. Goodrich, N. J. Halas, J. Phys. Chem. C 2009, 113, 12090. [91] H. Chen, L. Shao, T. Ming, Z. Sun, C. Zhao, B. Yang, J. Wang, Small 2010, 6, 2272. [92] W. Feng, L. Chen, M. Qin, X. Zhou, Q. Zhang, Y. Miao, K. Qiu, Y. Zhang, C. He, Sci. Rep. 2015, 5, 17422. [93] C. Guo, H. Yu, B. Feng, W. Gao, M. Yan, Z. Zhang, Y. Li, S. Liu, Biomaterials 2015, 52, 407. [94] K. M. Au, M. Chen, S. P. Armes, N. Zheng, Chem. Commun. 2013, 49, 10525. [95] B. Kim, J. Kim, E. Kim, Macromolecules 2011, 44, 8791. [96] J. Jang, J. Ha, B. Lim, Chem. Commun. 2006, 1622. [97] E. Ju, K. Dong, Z. Liu, F. Pu, J. Ren, X. Qu, Adv. Funct. Mater. 2015,\n25, 1574. [98] L. Wen, L. Chen, S. Zheng, J. Zeng, G. Duan, Y. Wang, G. Wang,\nZ. Chai, Z. Li, M. Gao, Adv. Mater. 2016, 28, 5072. [99] L. Zeng, Y. Pan, S. Wang, X. Wang, X. Zhao, W. Ren, G. Lu, A. Wu,\nACS Appl. Mater. Interfaces 2015, 7, 16781. [100] Z. Liu, L. Cheng, L. Zhang, Z. Yang, Z. Liu, J. Fang, Biomaterials\n2014, 35, 4099. [101] J. Li, J. Han, T. Xu, C. Guo, X. Bu, H. Zhang, L. Wang, H. Sun,\nB. Yang, Langmuir 2013, 29, 7102. [102] X. Zhang, X. Xu, T. Li, M. Lin, X. Lin, H. Zhang, H. Sun, B. Yang,\nACS Appl. Mater. Interfaces 2014, 6, 14552. [103] R. Zheng, S. Wang, Y. Tian, X. Jiang, D. Fu, S. Shen, W. Yang, ACS\nAppl. Mater. Interfaces 2015, 7, 15876. [104] D. Li, Y. Zhang, S. Wen, Y. Song, Y. Tang, X. Zhu, M. Shen,\nS. Mignani, J.-P. Majoral, Q. Zhao, X. Shi, J. Mater. Chem. B 2016, 4, 4216. [105] D. Jaque, L. M. Maestro, B. Del Rosal, P. Haro-Gonzalez, A. Benayas, J. Plaza, E. M. Rodriguez, J. G. Sole, Nanoscale 2014, 6, 9494. [106] X. Huang, M. A. El-Sayed, J. Adv. Res. 2010, 1, 13. [107] Q. Wang, J. Wang, G. Lv, F. Wang, X. Zhou, J. Hu, Q. Wang,\nJ. Mater. Sci. 2014, 49, 3484. [108] Y. Yong, X. Cheng, T. Bao, M. Zu, L. Yan, W. Yin, C. Ge, D. Wang,\nZ. Gu, Y. Zhao, ACS Nano 2015, 9, 12451. [109] H. Peng, S. Tang, Y. Tian, R. Zheng, L. Zhou, W. Yang, Part. Part. Syst. Charact. 2016, 33, 332. [110] S. Ye, G. Marston, J. R. McLaughlan, D. O. Sigle, N. Ingram,\nS. Freear, J. J. Baumberg, R. J. Bushby, A. F. Markham, K. Critchley, Adv. Funct. Mater. 2015, 25, 2117. [111] W. Zhu, K. Liu, X. Sun, X. Wang, Y. Li, L. Cheng, Z. Liu, ACS Appl. Mater. Interfaces 2015, 7, 11575. [112] X. Cai, W. Gao, L. Zhang, M. Ma, T. Liu, W. Du, Y. Zheng, H. Chen, J. Shi, ACS Nano 2016, 10, 11115.\nwww.advhealthmat.de\nAdv. Healthcare Mater. 2017, 1700073\nwww.advancedsciencenews.com\nP R O\nG R ES\nS R\nEP O\nR T\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimwileyonlinelibrary.com1700073 (20 of 20)\n[113] P. Huang, J. Lin, W. Li, P. Rong, Z. Wang, S. Wang, X. Wang, X. Sun, M. Aronova, G. Niu, Angew. Chem., Int. Ed. 2013, 125, 14208. [114] P. Wu, D. Deng, J. Gao, C. Cai, ACS Appl. Mater. Interfaces 2016, 8, 10243. [115] H. Liu, D. Nishide, T. Tanaka, H. Kataura, Nat. Commun. 2011, 2, 309. [116] A. L. Antaris, J. T. Robinson, O. K. Yaghi, G. Hong, S. Diao,\nR. Luong, H. Dai, ACS Nano 2013, 7, 3644. [117] K. Yang, H. Xu, L. Cheng, C. Sun, J. Wang, Z. Liu, Adv. Mater. 2012,\n24, 5586. [118] Y.-F. Wang, G.-Y. Liu, L.-D. Sun, J.-W. Xiao, J.-C. Zhou, C.-H. Yan,\nACS Nano 2013, 7, 7200. [119] W. Xu, Z. Meng, N. Yu, Z. Chen, B. Sun, X. Jiang, M. Zhu, RSC Adv.\n2015, 5, 7074. [120] G. Tian, X. Zhang, X. Zheng, W. Yin, L. Ruan, X. Liu, L. Zhou,\nL. Yan, S. Li, Z. Gu, Small 2014, 10, 4160. [121] C. Liang, S. Diao, C. Wang, H. Gong, T. Liu, G. Hong, X. Shi,\nH. Dai, Z. Liu, Adv. Mater. 2014, 26, 5646. [122] B. Zhang, H. Wang, S. Shen, X. She, W. Shi, J. Chen, Q. Zhang,\nY. Hu, Z. Pang, X. Jiang, Biomaterials 2016, 79, 46. [123] W. Fang, S. Tang, P. Liu, X. Fang, J. Gong, N. Zheng, Small 2012, 8, 3816. [124] C. Xu, S. Shi, L. Feng, F. Chen, S. A. Graves, E. B. Ehlerding,\nS. Goel, H. Sun, C. G. England, R. J. Nickles, Z. Liu, T. Wang, W. Cai, Nanoscale 2016, 8, 12683. [125] Y. Chao, G. Wang, C. Liang, X. Yi, X. Zhong, J. Liu, M. Gao, K. Yang, L. Cheng, Z. Liu, Small 2016, 12, 3967. [126] M. Chen, S. Tang, Z. Guo, X. Wang, S. Mo, X. Huang, G. Liu, N. Zheng, Adv. Mater. 2014, 26, 8210. [127] H. S. Jung, W. H. Kong, D. K. Sung, M.-Y. Lee, S. E. Beack, D. H. Keum, K. S. Kim, S. H. Yun, S. K. Hahn, ACS Nano 2014, 8, 260. [128] J. Yu, C. Yang, J. Li, Y. Ding, L. Zhang, M. Z. Yousaf, J. Lin, R. Pang, L. Wei, L. Xu, Adv. Mater. 2014, 26, 4114. [129] G. M. Santos, F. Zhao, J. Zeng, W.-C. Shih, Nanoscale 2014, 6, 5718. [130] V. P. Pattani, J. W. Tunnell, Lasers Surg. Med. 2012, 44, 675. [131] K.-C. Li, H.-C. Chu, Y. Lin, H.-Y. Tuan, Y.-C. Hu, ACS Appl. Mater.\nInterfaces 2016, 8, 12082. [132] W. Yang, W. Guo, W. Le, G. Lv, F. Zhang, L. Shi, X. Wang, J. Wang,\nS. Wang, J. Chang, B. Zhang, ACS Nano 2016, 10, 10245.\n[133] Z. Wang, P. Huang, O. Jacobson, Z. Wang, Y. Liu, L. Lin, J. Lin, N. Lu, H. Zhang, R. Tian, ACS Nano 2016, 10, 3453. [134] H. Chen, M. Song, J. Tang, G. Hu, S. Xu, Z. Guo, N. Li, J. Cui, X. Zhang, X. Chen, ACS Nano 2016, 10, 1355. [135] G. Song, J. Shen, F. Jiang, R. Hu, W. Li, L. An, R. Zou, Z. Chen, Z. Qin, J. Hu, ACS Appl. Mater. Interfaces 2014, 6, 3915. [136] W. Yin, L. Yan, J. Yu, G. Tian, L. Zhou, X. Zheng, X. Zhang, Y. Yong, J. Li, Z. Gu, ACS Nano 2014, 8, 6922. [137] L. Tan, S. Wang, K. Xu, T. Liu, P. Liang, M. Niu, C. Fu, H. Shao, J. Yu, T. Ma, X. Ren, H. Li, J. Dou, J. Ren, X. Meng, Small 2016, 12, 2046. [138] L. Yuwen, J. Zhou, Y. Zhang, Q. Zhang, J. Shan, Z. Luo, L. Weng, Z. Teng, L. Wang, Nanoscale 2016, 8, 2720. [139] Z. Huang, Y. Qi, D. Yu, J. Zhan, RSC Adv. 2016, 6, 31031. [140] Z. Lei, W. Zhu, S. Xu, J. Ding, J. Wan, P. Wu, ACS Appl. Mater. Interfaces 2016, 8, 20900. [141] G. Song, J. Hao, C. Liang, T. Liu, M. Gao, L. Cheng, J. Hu, Z. Liu, Angew. Chem., Int. Ed. Engl. 2015, 55, 2122. [142] M. Zhang, Y. Cao, L. Wang, Y. Ma, X. Tu, Z. Zhang, ACS Appl. Mater. Interfaces 2015, 7, 4650. [143] J. Zeng, M. Cheng, Y. Wang, L. Wen, L. Chen, Z. Li, Y. Wu, M. Gao, Z. Chai, Adv. Healthcare Mater. 2016, 5, 772. [144] C. M. MacNeill, E. M. Wailes, N. H. Levi-Polyachenko, J. Nanosci. Nanotechnol. 2013, 13, 3784. [145] C. M. MacNeill, R. C. Coffin, D. L. Carroll, N. H. Levi-Polyachenko, Macromol. Biosci. 2013, 13, 28. [146] L. Beqa, Z. Fan, A. K. Singh, D. Senapati, P. C. Ray, ACS Appl. Mater. Interfaces 2011, 3, 3316. [147] J. Bai, Y. Liu, X. Jiang, Biomaterials 2014, 35, 5805. [148] Z. Zhou, Y. Sun, J. Shen, J. Wei, C. Yu, B. Kong, W. Liu, H. Yang, S. Yang, W. Wang, Biomaterials 2014, 35, 7470. [149] W. Feng, X. Zhou, W. Nie, L. Chen, K. Qiu, Y. Zhang, C. He, ACS Appl. Mater. Interfaces 2015, 7, 4354. [150] Q. Tian, Q. Wang, K. X. Yao, B. Teng, J. Zhang, S. Yang, Y. Han, Small 2014, 10, 1063. [151] S. Bhana, G. Lin, L. Wang, H. Starring, S. R. Mishra, G. Liu, X. Huang, ACS Appl. Mater. Interfaces 2015, 7, 11637. [152] T. Liu, Y. Chao, M. Gao, C. Liang, Q. Chen, G. Song, L. Cheng,\nZ. Liu, Nano Res. 2016, 9, 3003.\nwww.advhealthmat.de\nAdv. Healthcare Mater. 2017, 1700073\nwww.advancedsciencenews.com"
    } ],
    "references" : [ {
      "title" : "Hyperthermia in Oncology",
      "author" : [ "C.L.K. Pang" ],
      "venue" : "CRC Press, Boca Raton, Florida",
      "citeRegEx" : "3",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "A",
      "author" : [ "G. Baronzio", "M. Jackson", "D. Lee" ],
      "venue" : "Szász, Conference Papers in Medicine 2013",
      "citeRegEx" : "5",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "ACS Nano 2011",
      "author" : [ "W.I. Choi", "J.-Y. Kim", "C. Kang", "C.C. Byeon", "Y.H. Kim", "G. Tae" ],
      "venue" : "5",
      "citeRegEx" : "11",
      "shortCiteRegEx" : null,
      "year" : 1995
    }, {
      "title" : "ACS Nano 2013",
      "author" : [ "Y. Wang", "K.C. Black", "H. Luehmann", "W. Li", "Y. Zhang", "X. Cai", "D. Wan", "S.-Y. Liu", "M. Li", "P. Kim" ],
      "venue" : "7",
      "citeRegEx" : "31",
      "shortCiteRegEx" : null,
      "year" : 2068
    }, {
      "title" : "Small 2016",
      "author" : [ "L. Tan", "S. Wang", "K. Xu", "T. Liu", "P. Liang", "M. Niu", "C. Fu", "H. Shao", "J. Yu", "T. Ma", "X. Ren", "H. Li", "J. Dou", "J. Ren", "X. Meng" ],
      "venue" : "12",
      "citeRegEx" : "137",
      "shortCiteRegEx" : null,
      "year" : 2046
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "201700073 depending on the area under treatment, the maximum temperature and the duration used vary.[3] Hyperthermia at midtemperatures (41.",
      "startOffset" : 100,
      "endOffset" : 103
    }, {
      "referenceID" : 0,
      "context" : "8–45 °C) is capable of exerting a therapeutic effect on malignant cells in hypoxic environments, while eliciting a minimum damage on the surrounding healthy tissues (reviewed in detail in[3]).",
      "startOffset" : 187,
      "endOffset" : 190
    }, {
      "referenceID" : 0,
      "context" : "Additionally, it can also be used to improve the therapeutic outcome of radio- and chemotherapy.[3] On the other hand, hyperthermia at hightemperatures (45–90 °C) can affect both cancer and normal cells, inducing cellular changes (e.",
      "startOffset" : 96,
      "endOffset" : 99
    }, {
      "referenceID" : 0,
      "context" : "enzymatic and mitochondrial dysfunctions) and ultimately necrosis (reviewed in detail in[3,4]).",
      "startOffset" : 88,
      "endOffset" : 93
    }, {
      "referenceID" : 1,
      "context" : "However, the equipment and techniques currently available to perform such types of hyperthermia-based treatments present some limitations and need further improvements for attaining a higher selectivity, tissue penetration, and effectiveness.[5] To accomplish that, researchers are currently developing new responsive nanomaterials that due to their small size (usually < 200 nm), can accumulate preferably in tumor and induce on-demand hyperthermia, after being subjected to an external stimulus (e.",
      "startOffset" : 242,
      "endOffset" : 245
    }, {
      "referenceID" : 3,
      "context" : "2-fold higher internalization by cancer cells than PEGylated gold nanocages and PEGylated GNR, respectively.[31] In contrast, under in vivo conditions, PEGylated gold nanocages displayed a low blood circulation time and a high liver uptake (≈ 62% ID g−1), which resulted in a low tumor accumulation (≈ 2.",
      "startOffset" : 108,
      "endOffset" : 112
    }, {
      "referenceID" : 3,
      "context" : "PEGylated gold nanocages and nanorods, respectively; [31]",
      "startOffset" : 53,
      "endOffset" : 57
    }, {
      "referenceID" : 2,
      "context" : "encapsulated GNR in photocrosslinked chitosan-pluronic F-68 conjugates and verified that this modification increases nanomaterials tumor accumulation from ≈ 12 to ≈ 117% ID g−1.[11] Due to their superior tumorhoming capacity, the PTT mediated by these nanodevices resulted in tumor eradication while when non-coated GNR were used only a slight decrease in the rate of tumor growth was noticed.",
      "startOffset" : 177,
      "endOffset" : 181
    }, {
      "referenceID" : 3,
      "context" : "[10,85] Regarding Pd and gold-based nanostructures, their photothermal capacity is influenced by their shape and this parameter has been optimized during nanostructures synthesis to obtain agents with an improved PTT capacity.[31,86] Xiao et al.",
      "startOffset" : 226,
      "endOffset" : 233
    }, {
      "referenceID" : 2,
      "context" : "Choi and co-workers observed that chitosan-pluronic F-68 conjugates encapsulating GNR are able to mediate tumor eradication with two laser irradiation sessions (at 24 and 48 h post-injection) while the application of one irradiation session (at 24 h post-injection) only resulted in a reduction of the tumor growth.[11] In another work, Zhou and co-workers noticed that PEGylated WO2.",
      "startOffset" : 315,
      "endOffset" : 319
    } ],
    "year" : 2017,
    "abstractText" : "DOI: 10.1002/adhm.201700073 depending on the area under treatment, the maximum temperature and the duration used vary.[3] Hyperthermia at midtemperatures (41.8–45 °C) is capable of exerting a therapeutic effect on malignant cells in hypoxic environments, while eliciting a minimum damage on the surrounding healthy tissues (reviewed in detail in[3]). Additionally, it can also be used to improve the therapeutic outcome of radioand chemotherapy.[3] On the other hand, hyperthermia at hightemperatures (45–90 °C) can affect both cancer and normal cells, inducing cellular changes (e.g. enzymatic and mitochondrial dysfunctions) and ultimately necrosis (reviewed in detail in[3,4]). However, the equipment and techniques currently available to perform such types of hyperthermia-based treatments present some limitations and need further improvements for attaining a higher selectivity, tissue penetration, and effectiveness.[5] To accomplish that, researchers are currently developing new responsive nanomaterials that due to their small size (usually < 200 nm), can accumulate preferably in tumor and induce on-demand hyperthermia, after being subjected to an external stimulus (e.g. magnetic field or light), with a high efficacy and safety.[6–10] Among the different nanomaterials explored, until now, to induce hyperthermia, some can mediate this effect by absorbing light, generated by a laser, and releasing its energy as heat (nanomaterials’ mediated photo thermal therapy (PTT)). This feature has been displayed by several types of nanostructures produced with gold, carbon, copper, molybdenum, tungsten, iron, palladium or conjugated polymers.[7,11–18] Moreover, different strategies are currently being explored to further enhance the photothermal potential of these nanostructures. Compared to laser-induced interstitial thermotherapy (a therapeutic modality that only employs laser light to thermally ablate tumors), nanomaterials’ mediated PTT is less invasive, demands radiation with a lower intensity and its therapeutic outcome is less dependent on the characteristics of the irradiated tissue (e.g. water or hemoglobin content).[19] In addition, PTT mediated by nanomaterials can potentially achieve a higher selectivity towards cancer cells through the use of precisely engineered nanostructures that are specifically internalized by diseased cells.[20–22] Still, it should be noted that the clinical translation of these photothermal agents is challenging since only recently the clinical safety profile of The deployment of hyperthermia-based treatments for cancer therapy has captured the attention of different researchers worldwide. In particular, the application of light-responsive nanomaterials to mediate hyperthermia has revealed promising results in several pre-clinical assays. Unlike conventional therapies, these nanostructures can display a preferential tumor accumulation and thus mediate, upon irradiation with near-infrared light, a selective hyperthermic effect with temporal resolution. Different types of nanomaterials such as those based on gold, carbon, copper, molybdenum, tungsten, iron, palladium and conjugated polymers have been used for this photothermal modality. This progress report summarizes the different strategies that have been applied so far for increasing the efficacy of the photothermal therapeutic effect mediated by nanomaterials, namely those that improve the accumulation of nanomaterials in tumors (e.g. by changing the corona composition or through the functionalization with targeting ligands), increase nanomaterials’ intrinsic capacity to generate photoinduced heat (e.g. by synthesizing new nanomaterials or assembling nanostructures) or by optimizing the parameters related to the laser light used in the irradiation process (e.g. by modulating the radiation wavelength). Overall, the development of new strategies or the optimization and combination of the existing ones will surely give a major contribution for the application of nanomaterials in cancer PTT.",
    "creator" : "Adobe InDesign CS6 (Macintosh)"
  }
}